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ABSTRACT
Developing diagnostic modalities that utilize nanomaterials and miniaturized
detectors can have an impact in point-of-care diagnostics. Diagnostic systems that (i) are
sensitive, robust, and portable, (ii) allow detection in clinical samples, (iii) require
minimal sample preparation yielding results quickly, and (iv) can simultaneously
quantify multiple targets, would have a great potential in biomedical research and public
healthcare. Bacterial infections still cause pathogenesis throughout the world (Chapter I).
The emergence of multi-drug resistant strains, the potential appearance of bacterial
pandemics, the increased occurrence of bacterial nosocomial infections, the wide-scale
food poisoning incidents and the use of bacteria in biowarfare highlight the need for
designing novel bacterial-sensing modalities.
Among the most prominent disease-causing bacteria are strains of Escherichia
coli, like the E. coli O157:H7 that produces the Shiga-like toxin (Stx). Apart from
diarrheagenic E. coli strains, others cause disease varying from hemolytic uremic
syndrome and urinary tract infections to septicemia and meningitis. Therefore, the
detection of E. coli needs to be performed fast and reliably in diverse environmental and
clinical samples. Similarly, Mycobacterium avium spp. paratuberculosis (MAP), a
fastidious microorganism that causes Johne’s disease in cattle and has been implicated in
Crohn’s disease (CD) etiology, is found in products from infected animals and clinical
samples from CD patients, making MAP an excellent proof-of-principle model.
Recently, magnetic relaxation nanosensors (MRnS) provided the first applications
of improved diagnostics with high sensitivity and specificity. Nucleic acids, proteins,
viruses and enzymatic activity were probed, yet neither large targets (for instance
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bacterial and mammalian cells) nor multiple bacterial disease parameters have been
simultaneously monitored, in order to provide thorough information for clinical decision
making. Therefore, the goal of this study was to utilize MRnS for the sensitive
identification of multiple targets associated with bacterial pathogenesis, while monitoring
virulence factors at the microorganism, nucleic acid and virulence factor levels, to
facilitate improved diagnosis and optimal treatment regimes. To demonstrate the
versatility of MRnS, we used MAP as our model system, as well as several other
pathogens and eukaryotic cell lines.
In initial studies, we developed MRnS suitable for biomedical applications
(Chapter II). The resulting MRnS were composed of an iron oxide core, which was caged
within a biodegradable polymeric coating that could be further functionalized for the
attachment of molecular probes. We demonstrated that depending on the polymer used
the physical and chemical properties of the MRnS can be tailored. Furthermore, we
investigated the role of polymer in the enzyme- mimicking activity of MRnS, which may
lead to the development of optimized colorimetric in vitro diagnostic systems such as
immunoassays and small- molecule-based screening platforms.
Additionally, via facile conjugation chemistries, we prepared bacterium- specific
MRnS for the detection of nucleic acid signatures (Chapter III). Considering that MAP
DNA can be detected in clinical samples and isolates from CD patients via laborious
isolation and amplification procedures requiring several days, MRnS detected MAP’s
IS900 nucleic acid marker up to a single MAP genome copy detection within 30 minutes.
Furthermore, these MRnS achieved equally fast IS900 detection even in crude DNA
extracts, outperforming the gold standard diagnostic method of nested Polymerase Chain

iv

Reaction (nPCR). Likewise, the MRnS detected IS900 with unprecedented sensitivity
and specificity in clinical isolates obtained from blood and biopsies of CD patients,
indicating the clinical utility of these nanosensors.
Subsequently, we designed MRnS for the detection of MAP via surface-marker
recognition in complex matrices (Chapter III). Milk and blood samples containing
various concentrations of MAP were screened and quantified without any processing via
MRnS, obtaining dynamic concentration-dependent curves within an hour. The MAP
MRnS were able not only to identify their target in the presence of interferences from
other Gram positive and Gram negative bacteria, but could differentiate MAP among
other mycobacteria including Mycobacterium tuberculosis. In addition, detection of MAP
was performed in clinical isolates from CD patients and homogenized tissues from
Johne’s disease cattle, demonstrating for the first time the rapid identification of bacteria
in produce, as well as clinical and environmental samples.
However, comparing the unique MAP quantification patterns with literatureavailable trends of other targets, we were prompted to elucidate the underlying
mechanism of this novel behavior (Chapter IV). We hypothesized that the nanoparticle
valency – the amount of probe on the surface of the MRnS – may have modulated the
changes in the relaxation times (ΔΤ2) upon MRnS – target association. To address this,
we prepared MAP MRnS with high and low anti-MAP antibody levels using the same
nanoparticle formulation. Results corroborated our hypothesis, but to further bolster it we
investigated if this behavior is target-size- independent. Hence utilizing small- moleculeand antibody-carrying MRnS, we detected cancer cells in blood, observing similar
detection patterns that resembled those of the bacterial studies. Notably, a single cancer
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cell was identified via high- valency small- molecule MRnS, having grave importance in
cancer diagnostics because a single cancer cell progenitor in circulation can effectively
initiate the metastatic process. Apart from cells, we also detected the Cholera Toxin B
subunit with valencly-engineered MRnS, observing similar to the cellular targets’
diagnostic profiling behavior.
Finally, as bacterial drug resistance is of grave healthcare importance, we utilized
MRnS for the assessment of bacterial metabolism and drug susceptibility (Chapter V).
Contrary to spectophotometric and visual nanosensors, their magnetic counterparts were
able to quickly assess bacterial carbohydrate uptake and sensitivity to antibiotics even in
blood. Two MRnS-based assay formats were devised relying on either the Concanavalin
A (Con A)- induced clustering of polysaccharide-coated nanoparticles or the association
between free carbohydrates and Con A-carrying MRnS. Overall, taking together these
results, as well as those on pathogen detection and the recent instrumentation
advancements, the use of MRnS in the clinic, the lab and the field should be anticipated.
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CHAPTER I: GENERAL INTRODUCTION UNWRAPING THE BOX
OF BACTERIAL PATHOGENESIS
Bacteria and other infectious agents inflict human pathogenesis and mortality
throughout the world, exceeding cardiovascular diseases and cancer1 . Despite the great
progress in sanitation, as well as identification and control of several infections diseases
in developed countries, problems persist with food contamination, hospital-acquired
pathogens, and sexually transmitted diseases2, 3 . In the developing countries of subSahara Africa and Southeast Asia, but even in remote areas of Western countries,
infectious diseases primarily occur due to poor sanitation and lack of sensitive and
efficient technologies to rapidly identify and treat these conditions2, 3 . Additional reasons
that contribute to the extensive transmission of infectious diseases include living close to
infected animals and contaminated water, and the socioeconomic trends and political
instability often observed in many developing nations4 . Therefore, upgrading the living
conditions and diagnostic protocols in poor rural areas is critical in controlling the spread
of disease before becoming pandemic. Also, as modern global traveling facilitates the
spread of disease faster than ever, developing fast, simple and accurate methods to
identify infectious diseases at the points-of-care is of major importance.
Bacteria, as well as other infectious agents, are capable of causing disease with
symptoms that can be manifested within minutes, or after a couple of hours to days or
even years after the initial infection. These pathogenic agents are subject to transmission
from either an infected individual or vector (such as ticks and birds) to a healthy
individual4 . The complexity and plethora of pathogens that cause disease, in addition to
the prolonged incubation time before manifestation of clinical symptomology, make the
1

diagnosis of some of these conditions challenging. In general though, infectious agents
can be classified within groups, depending on their nature, size, phenotype, transmission
routes and genetic makeup (Table 1 and Figure 1).

Table 1 The repertoire of infectious agents.
Differences in size, morphology, infection mode, pathogenesis mechanisms, clinical
symptomology and disease highlight the need for development of sensitive and specific
pathogen identification modalities in diverse settings.
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Current technologies for bacterial diagnosis and their limitations
Traditionally, the presence of bacteria in a clinical sample is determined via
microscopy usually after growth in pure culture, followed by growth in differential media
and biochemical tests to confirm the microorganism’s identity. Despite their specificity,
these methods have limitations. For instance, samples with high pathogen loads are
needed for microscopy-based methods. Second, growth pattern methods require at least a
24-hour incubation period to provide results. Third, as some microorganisms cannot grow
easily in culture, their identification is daunting.
In order to circumvent these limitations, with the discovery of DNA and the
development of Polymerase Chain Reaction (PCR), microbiologists adopted a molecularbased diagnostic frameset in the last quarter of the 20th century. Specifically, instead of
looking for the microorganism as an entity itself, they started looking for genes
associated with its virulence and disease patterns. Consequently, there was a rise in
genome sequencing and the deposition of the annotated genome in databases4 . Based on
this information, DNA microarrays have been developed, identifying DNA segments
corresponding to an organism’s genome. These methodologies are highly sensitive and
selective, achieving detection down to the single pathogen. Despite this, the major
limitation of the gene chip is that it cannot provide critical information about the
pathogen’s specific RNA (transcriptional) and protein (translational) levels. Furthermore,
it cannot address how these parameters are modulated by factors and processes that may
alter the microorganism’s growth, as well as how the host’s immune response affects the
microorganism’s expression patterns at the transcriptional and translational levels. Apart
from PCR, several other molecular diagnostic methods have been introduced, such as
3

RAPID-PCR, checkerboard hybridization, ligase chain reaction, ribotyping using
restriction length polymorphisms, and pulsed-field gel electrophoresis4 . Despite their
distinct advantages, all of these methods require undamaged and highly pure microbial
DNA and have to be performed in a laboratory setting by experienced personnel using
expensive instrumentation and reagents. Therefore, the associated cost of these molecular
diagnostic modalities is high enough to prohibit their wide-scale use at the points-of-care
and in developing nations.
In addition to microscopy- or nucleic-acid-based techniques, the identification of
a pathogen can be achieved via immunoassays targeting specific proteins or
carbohydrates moieties unique to the pathogen. Such methods include agglutination tests,
fluorescent immunoassays, enzyme- linked immunosorbent assays (ELISA) and Western
blot analyses4 . Although these methods are very sensitive, they detect a pathogen’s
molecular ‘fingerprints’, such as proteins and cell wall epitopes. Hence, as these assays
do not provide any direct information about the presence and metabolic state of a
microorganism, the administration of suitable antibiotics or other therapeutic agents
cannot be achieved. Additionally, as these methods regularly utilize an antibody for the
recognition of bacterial targets, proper handling and storage is needed in order to prevent
antibody denaturation. Furthermore, these assays are affected by the clinical sample’s
nature, because the specimen, for instance blood, often times needs to undergo processing
before being analyzed. Similarly, flow cytometry 5-7 and phage typing 6 face limitations
imposed by the sample’s characteristics, as optically opaque or viscous samples can
interfere with the readout, whereas the assay’s portability is hindered by the bulky
instrumentation. Likewise, magnetic micro-beads have been used for the magnetic
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separation and identification of microbes through PCR and flow cytometry7, 8 , yet these
methods require several intermediate steps and have limited capabilities in complex
biological samples.
Pathogenesis caused by intracellular pathogens, such as Mycobacterium
tuberculosis among others, relies on the survival of the microorganism within host cells,
including macrophages, dendritic cells and T helper cells9 . This mode of infection and the
frequent absence of clinical symptomology hamper these pathogens’ detection and
prevent treatment and containment. Consequently, the physician cannot proceed to the
assignment of an appropriate treatment course, delaying the clearance of the pathogen
from the body. Current tests cannot detect intracellular pathogens in biological fluids,
such as the blood and lymph fluid, as most of these tests are based on fluorescence
emission in the absence of optical interference. Hence, the need for developing opticalindependent diagnostic modalities is pivotal for the detection of intracellular pathogens in
body fluids and biopsies, with no or minimal sample preparation steps. Furthermore,
these modalities should be able to facilitate multi-sensing capabilities, detecting not only
the microorganism per se, but its genomic fragments and protein markers. This could
corroborate bacterial identification and prevent misdiagnosis due to cross-reactivity 4 that
tends to be common in serological assays.

The challenge of detecting toxins
Toxins are virulence factors that affect the host cell’s physiological processes and
plasma membrane integrity, causing cytotoxicity10 . For instance, toxins, like listeriolysin
O from L. monocytogenes, create pores in and disrupt the phospholipid bilayer, causing
host cell’s lysis11 . Other toxins, such as Shiga toxin, inhibit protein synthesis, which in
5

turn activate apoptotic and necrotic cascades12, 13 . Furthermore, toxins, like anthrax and
botulism, alter the host cell’s signal transduction cascades. These alterations initiate the
disease state and ultimately lead to the host cell’s death14 . Hence through exploitation of
numerous mechanisms, bacterial toxins affect host cell’s homeostasis and induce cell
death, aiming to the release of nutrients needed for microbial survival and colonization.
Particularly, intracellular pathogens that have a potent toxin in their virulence repertoire
utilize the toxin as a key exit mechanism, a tool for further infection and manifestation
within the body.
As toxins can cause significant pathogenesis, developing sensitive, fast and
reliable diagnostics methods could minimize their harmful effects. Most importantly,
toxins might remain in environmental, food or clinical samples long after the
corresponding pathogen secreted them. Therefore, screening these samples for the
presence of active toxins is

highly important to minimize intoxication and economic

losses, particularly during a pandemic. Current toxin detection methods utilize antibodyantigen interactions in ELISA15 , Western blots16,
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, antibody microarrays18 , surface

plasmon resonance biosensors19 , and antibody-coated polystyrene microbeads20 . These
methods are relatively sensitive and have multiplexing capabilities, but require
homogeneous or purified samples. Although time-consuming and laborious, these
purification procedures are critical for assay sensitivity and specificity, as they minimize
background noise. A major limitation of these assays is their spectrophotometric or
fluorimetric determination mode. Thus, limited biological and environmental samples can
be screened. To circumvent this obstacle, toxin detection techniques that utilize mass
spectrometry, such as Liquid Chromatography Mass Spectrometry (LC-MS)

6
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and

Multidimensional Protein Identification (MudPIT)22 , have been developed and achieved
high sensitivities. However, the lack of portability and user-friendliness, as well as the
sophisticated instrumentation, prevent the broader use of these diagnostic methods.

Limitations of current technologies and the rise of nanotechnology
Conventional molecular diagnostic techniques are widely used in laboratories
throughout the world to identify pathogenic agents with high sensitivity and
reproducibility. However, most of these techniques cannot be utilized in the field (e.g.
airports and food distribution centers) or in developing countries where resources are
scarce, because they require sophisticated, expensive instrumentation that needs to be
used by trained personnel. Additionally, the high cost and short shelf life of some
reagents, such as enzymes and DNA primers, limit the application of most conventional
pathogen detection techniques in developing nations. Furthermore, despite their
sensitivity, current technologies, like ELISA and PCR, require extensive sample
preparation and have long readout times, which delay prompt response and disease
containment.
Hence considering these, nanotechnology presents a great opportunity to develop
fast, accurate and cost effective diagnostics for the detection of pathogenic infectious
agents23, 24 . Due to the presence of unique properties in nanoscale materials, devices able
to report the presence of a pathogenic agent in clinical or environmental samples can be
designed. The properties observed in nanomaterials are different from those observed in
the bulk (micron-size) material due to their small size (1-100 nm) and large surface area,
resulting in enhanced surface reactivity, quantum confinement effects, increased
7

electrical conductivity and improved magnetic properties, among others24 . Most
importantly, modifications of the nanostructures’ surface can alter dramatically some of
their properties25, 26 . Hence, a single binding event can be potentially recorded.
Apart from striving for sensitivity and speed, nanotechnologists have geared their
efforts towards the development of nanotechnology-based systems that are affordable,
robust and reproducible, making them suitable for applications even in rural areas of
developing nations. For instance, researchers try to formulate cheap and stable
nanoparticles via novel facile synthetic routes, making nanoparticle-based diagnostic
assays globally accessible and deliverable. Moreover, using innovative approaches,
nanotechnology has the potential to build assays that can be performed in opaque media,
like blood and milk, without any sample preparation, providing fast and reliable results in
simple and user- friendly formats.

Popular nanotechnologies
The properties of the nanomaterials can be tailored by changing the size, shape,
composition and surface modification of the nanomaterial. Particularly, their electronic,
spectroscopic (emissive, absorptive), light scattering and conductive properties can be
modified by engineering the nanoparticles’ structural parameter, including their size,
composition, self assembly and binding properties24 . Below, some of the most commonly
used nanosystems are described. It should be noted that a particular nanosystem, for
example a nanoparticle of 100 nm in size including its coating and targeting ligands, can
be designed to sense targets that might be smaller (i.e. lipids), bigger (i.e. bacteria) or of
equal size (viruses) to the nanoparticle (Figure 1).
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Figure 1. Size distribution of widely used nanosystems in comparison with the most
common types of infectious disease agents.
A particular nanoparticle (represented by a black horizontal dashed line) could interact
with targets of various sizes, such as peptides, toxins, viruses and bacteria (blue, grey,
green and orange dashed lines, respectively). In this particular case, the nanoparticle has a
size of 100 nm, whereas virulence factors and disease markers are smaller (e.g. lipids,
peptides, DNA, toxins), and pathogens can be of roughly equal (e.g. most viruses) or
bigger size than the nanoparticle (e.g. bacteria, fungi).
Gold nanoparticles
Gold nanoparticles (Au-NP) can be synthesized either in an aqueous or organic
environment27 . Conventional techniques for aqueous synthesis involve the reduction of
AuCl3 with trisodium citrate, followed by the addition of a capping agent to stabilize the
Au-NP by introducing adequate electrostatic repulsion between individual particles to

9

keep them well dispersed in the medium27 . Alternatively, organic-based Au-NP synthesis
offers excellent control and improved size uniformity27 . Surface chemistries of Au-NP
can be controlled by grafting functionalized organic thiol molecules or thiol-containing
polymers, as the gold surface exerts strong affinity towards sulfhydryl groups leading to
the formation of relatively strong covalent bonds. Hence, further surface modification can
be done simply by using thiolated functional molecules, facilitating conjugation of
various probes, including antibodies and nucleic acids. Successful formation of Au NPs is
associated with the presence of a surface plasmon band in the preparation’s UV- vis
absorbance profile. The surface plasmon band arises from the coherent existence of free
electrons in the conduction band, due to the small particle size. The band shift depends on
the particle size, chemical surrounding, adsorbed species on the surface, and dielectric
constant28 . Changes in the local dielectric constant of the nanoparticles by absorbed
biomolecules or the biomarker- induced agglomeration of the nanoparticles cause
plasmonic band shifts28 . Hence, this unique characteristic of gold, as well as silver,
nanoparticles allows the use of the surface plasmon band shifts changes for several
diagnostic applications by recording the alterations in the UV- vis absorbance spectrum.
Apart from absorption, gold nanoparticles were used as tags for the detection and
quantification of numerous targets using fluorescence, Raman scattering, electrical
conductivity, atomic and magnetic force techniques23, 24 .

Silver nanoparticles
Silver nanoparticles (Ag-NP) were first used as a new generation of antimicrobial
agents to prevent infections29 . Generally, these nanoparticles can be synthesized using
methods

yielding

spherical,

elongated

(rod-shaped)
10

or

truncated

(triangular)

nanoparticles29 . Initially, silver seeds can be prepared by rapidly injecting 10 mM NaBH4
into an aqueous solution of 10 mM AgNO 3 and 1 mM sodium citrate and aged for 1.5 h29 .
Spherical silver nanoparticles can be prepared by reducing an aqueous solution of AgNO 3
(1 mM) by adding silver seed solution and aqueous solution of sodium citrate, under
boiling conditions until the color of the solution becomes greenish-yellow29 . Similarly,
the elongated and triangular shaped silver nanoparticles can be prepared by adding silver
seed, 0.1 M ascorbic acid, 0.1 M CTAB and 1 M NaOH solution to the aqueous solution
of AgNO3 (10 mM) to accelerate particle growth28, 30 . The in situ reduction of Ag+ ions
and introduction of surface functional groups can be achieved in one-pot reactions, using
various biopolymers. Other than small reducing agents, such as sodium citrate and
hydrazine hydrate, various functional polymers, including poly(acrylonitrile), poly(Nvinyl pyrrolidone), poly(vinyl alcohol), polyacrylic acid and polyacrylamide, were used
for the reduction and surface coatings of the silver ions31 . Hence, these functional Ag-NP
can perform conjugation chemistries to connect various targeting ligands, such as
proteins, antibodies, peptides, oligonucleotides and small molecules. Ag-NP exhibit a
surface plasmon band, usually at 422 nm for spherical nanoparticles, which can be used
for colorimetric detection and quantification of targets. Also, these nanoparticles can be
used for the microscopic identification of targets using either high angle annular dark
field (HAADF) or scanning transmission electron microscopy (STEM), and
electrochemical approaches.
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Quantum dots
Fluorescent quantum dots (Qdots) are semiconductors with unique optical
properties when compared to conventional semiconductors, organic fluorescent dyes and
proteins24 . Qdots can be prepared using a variety of methods ranging from molecular
beam epitaxy and electron beam lithography, yet colloidal synthesis is the most common
technique for Qdots preparation. Specifically, in the case of hot solution phase synthesis,
periodic group II and VI (CdSe, CdTe, ZnSe, etc) or III and V elements (InP, InAs, etc),
are dissolved in a solution with a stabilizing agent or polymer. Thus during the synthesis
procedure, these salts enter into a phase where they associate, leading to the formation of
core-shell Qdots capped with either a polymer or a stabilizer32 . Furthermore, a simple
‘cap exchange’ approach can be used to anchor for instance bifunctional mono- or dithiols to the Qdot surface, where the remaining functional end-group can be used for
further functionalization and conjugation. Mechanistically it is the band-gap that
determines in which frequencies the Qdot will respond to. Hence, by engineering their
band-gap (such as by changing their size), Qdots can emit light in different wavelengths
upon excitation, having broad and diverse applications. For instance, simply by
modulating their size, Qdots can be excited at a given wavelength and have tunable
emission from the ultra- violet (UV) to the near infra-red (NIR) region. Apart from being
tunable, Qdots are highly bright and extremely photostable, making them suitable for
various biomedical applications, such as sensing and detection of biomarkers,
immunolabeling of cells and tissues, detection of cancer in vitro and in vivo33-37 . Qdotbased FISH (Fluorescence In Situ Hybridization) probes have been widely used for the
detection of the Y-chromosome in fixed human sperm cells38 . Furthermore, Qdot-FRET12

based nanosensors mediated the ultrasensitive detection of low concentrations of target
DNA in the diagnosis of genetic diseases39, 40 .

Fluorescent polymeric nanoparticles
Polymeric nanoparticles are easily prepared using a linear or branched polymer
that promotes the encapsulation of a fluorophore within the nanoparticle’s cavity or
hydrophobic microdomains41-43 . Several synthetic routes can be utilized yielding stable
monodispersed nanoparticles in aqueous media. The resulting nanoparticles, such as
fluorescent silica ones, can be filtered and concentrated. Since the presence of the
polymeric coating protects the fluorophore, these nanoparticles are stable under diverse
conditions41-43 , surpassing organic dyes in photostability and versatility. Additionally the
presence of functional groups on the polymer coating, including amines, carboxylic acids
and esters, confers facile attachment of probes. Surface functionalization and targeting
can be achieved via numerous conjugation chemistries, including “click” and
carbodiimide44 . Detection is mainly achieved with the use of a fluorescence spectrometer,
flow cytometer, and fluorescence-recording microtiter plate reader41-43 .

Nanochips and Nanoarrays
Nanochips can be prepared for the fast identification of biomolecules, using AuNP or Ag-NP supported on thin silicon layers23,

24

. Following sample incubation, the

nanochips are subjected to different procedures in order to achieve signal amplification.
Due to their small size and use of currently available instrumentation, nanochips can
screen samples in a high- throughput format requiring minute sample volumes23,

13

45

.

Furthermore, apart from quantifying a target, nanochips can identify if proteins undergo
post-translational modifications, such as proteolytic cleavages and phosphorylation, using
matrix-assisted laser desorption/ionization-time-of- flight mass spectrometry (MALDITOF-MS)23 .
In addition to nanochips, nanoarrays have been used to further expand the
emerging field of DNA arrays23,

24, 46

. Through different manufacturing approaches,

nanoarrays have been fabricated using inkjet printing, electrochemistry, microfabricated
surface patterning, or photolithography with either pre-assembled masks or micromirrorbased apparatus23 . Specifically, the nanoarray can be constructed on diverse surfaces,
such as silicon, silanes, hydrogels, metallic and polydimethylsiloxane (PDMS), among
others. Hence, detection of a target can be achieved with atomic force microscopy
(AFM), surface plasmon resonance, optical waveguides, nanowires, microfluidics and
electrical current detectors. The nanoarray can utilize various probes, including antibody,
nucleic acid and small molecule, which can be either deposited in 1 – 30 μm droplets or
via fluidics-enhanced molecular transfer operation46 . In addition to these entities, colloids
and Qdots can be further applied leading to the construction of multiplexed nanoarrays
capable of screening minute samples in large libraries of potential pathogenic agents or
therapeutics.

Fiber-optic-based biosensors
For the rapid detection of analytes, researchers have modified traditional ELISA
plate

assays,

developing

sandwich- format

fiber-optic-based

platforms47-49 .

Immobilization of a capturing moiety (antibody, aptamer, ligand) to a fiber optic or
capillary tube mediates the capturing of the molecule of interest, whereas a secondary
14

probe (i.e. antibody) conjugated to a fluorophore facilitates target detection. Following
fluorophore excitation, the emitted light is recorded by portable instrumentation, which
can quantify the target based on the fluorescence intensity48 .

Cantilever-based arrays
Due to their high sensitivity, cantilevers can be used for the detection of
molecular targets. These cantilevers resemble AFM tips and can be decorated with
nucleic acids, small molecules and antibodies23,

24

. Upon binding of a target, the

cantilever deflects a couple of nanometers, facilitating detection. Since the deflection is
proportional to the amount of target binding, cantilever-based arrays are quantitative23, 24 .
Advantages of these arrays include the absence of any enzymatic amplification steps such
as PCR, the detection of nucleic acids and proteins without the need of labels (i.e.
fluorophores), and the ability to be used in microfluidic setups.

Magnetic nanoparticles
Magnetic nanoparticles have been used for a long time in the clinic and the
molecular biology laboratories23,

24

. For instance, superparamagnetic iron oxide

nanoparticles, composed of a magnetite/maghemite core, have been utilized as contrast
agents for magnetic resonance imaging (MRI). Also, magnetic nanoparticles conjugated
to antibodies have been used for the immunomagnetic separation of nucleic acids,
proteins, viruses, and cells23,

24

. Iron oxide nanoparticles are primarily synthesized via

water-based protocols, involving the alkaline precipitation of iron salts. To enhance water
stability and add surface functionality, often times the iron oxide core is coated with
polymers, such as dextran, polyacrylic acid and silica. Further surface modification can
15

facilitate the addition of functional groups, such as amino and carboxylic acids, making
subsequent conjugations easy. Hence, iron oxide nanoparticles can carry diverse ligands,
such as peptides, small molecules, proteins, antibodies and nucleic acids. Iron oxide
nanoparticles have been used for the identification and quantification of several targets,
including mRNA, DNA, and viruses50-52 . Furthermore, enzymatic activities were
monitored with these nanoparticles53,

54

. Detection with magnetic nanoparticles can be

achieved with the use of magnetometers or superconducting quantum interference device
(SQUID), which record alterations in the magnetic properties of the particles upon
molecular interactions with a target55-57 . Also, detection and quantification can be
accomplished with magnetic relaxometers and magnetic resonance imaging (MRI), by
monitoring the changes in the spin-spin relaxation time (T2) of the solution’s water
protons due to nanoparticle association with a target50, 52, 58 .
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CHAPTER II: DEVELOPMENT OF MRnS FOR BIOMEDICAL
APPLICATIONS

Introduction
Iron oxide-based magnetic nanoparticles have been widely used in a variety of
biomedical applications, including magnetic separation, magnetic resonance imaging,
hyperthermia,

magnetically- guided drug delivery, tissue repair, and

molecular

diagnostics50-52, 59-63 . For most applications, a polymeric coating is needed to improve the
nanoparticles’ aqueous stability, biocompatibility and conjugation properties. For
instance, dextran-coated iron oxide nanoparticles have been successfully used as
magnetic resonance imaging (MRI) contrast agents, due to their strong ability to dephase
water protons in surrounding tissue, which results in a decrease in the MRI signal50 . An
interesting feature of these nanoparticles is that the dextran coating can be crosslinked
and functionalized with amino groups to facilitate the conjugation of targeting ligands for
MRI and in vitro diagnostics applications64 . Generally, current synthetic procedures for
polymer-coated iron oxide nanoparticles involve the formation of the iron oxide core in
the presence of the polymer that serves as a stabilizer and capping agent in an alkaline
solution65 . Under these in situ conditions, the nature, quality and amount of the polymer
modulate the nucleation, growth and size of the newly formed iron oxide nanocrystal.
Hence, understanding the polymer’s potential role on the iron oxide nanoparticles’
intrinsic properties during a stepwise synthesis may be equally important, as it could
potentially facilitate the formation of application-tailored iron oxide nanoparticles.
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Considering these, we optimized the water-based synthesis of polymer-coated
iron oxide nanoparticles (IONP) and investigated how their properties are affected by
their polymeric coating. Among the physical parameters studied were the size, shape, and
spin-spin relaxivity (R2). Lastly, we examined whether the nanoparticles’ polymeric
coating could modulate their enzyme- mimicking activity, paving the road for
nanoparticle-based immunoassays.

Materials and Methods
Reagents.
Iron salts (FeCl2 . 4H2 O and FeCl3 . 6H2 O), polyacrylic acid (1.8 kDa), Concanavalin A
and TMB (3,3’,5,5’-Tetramethylbenzidine) were purchased from Sigma. Dextrans (10
kDa) were received from Amersham Biosciences/Pharmacosmos and Sigma. TEOS:
tetraethylorthosilicate (Fluka), APTS: 3-(amino-propyl)triethoxysilane (Aldrich) and
THPMP: 3-(trihydroxysilyl)propylmethyl-phosphate (Gelest Inc.) were used as received
from the suppliers.

Synthesis of iron oxide nanoparticles.
An acidic solution of iron salts containing 0.203 g FeCl2 . 4H2 O and 0.488 g FeCl3 . 6H2 O
in HCl solution (88.7 µl 12 N HCl in 2 ml water) was mixed with ammonium hydroxide
(830 µl NH4 OH in 15 ml DI water) under stirring conditions. The reaction mixture turned
black instantaneously, and after 30 seconds of stirring dextran (5 g in 10 ml DI water)
was added to yield dextran-coated IONP. Likewise, for the synthesis of polyacrylic-acidcoated IONP, polyacrylic acid (820 mg in 5 ml DI water) was added to the iron salt
solution 30 seconds after addition of ammonium hydroxide. For silica-coated IONP, a
18

TEOS-THPMP-APTS solution was added (6180 μl THPMP, 2680 μl TEOS, 670 μl
APTS) 20 seconds after initiation of the iron oxide nanocrystal formation. The resulting
solutions were stirred for 1 hr and then centrifuged at 13,000 rpm for 30 minutes to
remove large particulates. Finally, the supernatant was collected, washed several times
with distilled water and concentrated through an Amicon 8200 cell (Millipore
ultrafiltration membrane YM – 30 k)..

Characterization.
The particles were characterized using HRTEM (FEI TECNAI F30), a PDDLS
CoolBatch 40T instrument with the Precision Deconvolve 32 software, and a PerkinElmer Spectrum 100 FT-IR spectrometer using samples spotted on plastic cover slips. T2
was measured using a Bruker Minispec mq20 NMR analyzer operating at 0.47 T.

Kinetic assay of iron oxide nanoparticles’ peroxidase activity.
The peroxidase activity of the IONP was evaluated via steady-state kinetic assays at room
temperature. Specifically, serial dilutions of TMB were prepared in citrate buffer (pH 4),
and 100 μl aliquots were dispensed in a 96-well plate. Subsequently, aliquots of the
polymer-coated IONP, having equal iron concentrations (2 μg per ml), were added to the
corresponding wells. After addition of 25 μl H2 O2 (30%), each well’s absorbance was
recorded at 652 nm, using the time-scan mode of a Synergy HT microtiter plate reader
(Biotek).The kinetic parameters were determined via the Michaelis-Menten equation:

ν = Vmax × [S]/(Km + [S]),
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where ν is the initial rate of reaction, Vmax is the maximum rate of reaction, [S] is the
substrate’s concentration, and Km is the Michaelis constant.

Results
In our first set of experiments, we optimized the synthetic protocol, determining
the optimal addition time of the polymer. Our water-based synthetic protocol involved an
acid-base reaction between an acidic solution of iron salts and a basic solution of
ammonium hydroxide. Upon mixing, the resulting solution became alkaline (pH = 9.0),
facilitating the formation of iron oxide nanocrystals. This initial formation of
nanocrystals can occur either in the presence (in situ) or absence (stepwise) of a polymer.
Since most synthetic procedures that yield stable and monodispersed nanoparticles use an
in situ approach, we opted to follow this approach first, yet obtaining spherical
nanocrystals of 20 ± 5 nm in diameter with poor R2 relaxivity (< 1 mMs-1 ).
As this poor relaxivity contrasts with the relaxivity obtained with published in situ
procedures (60 – 100 mM-1 s-1 ), we investigated if a stepwise approach could result in
larger iron oxide nanocrystals with improved R2 relaxivities. In this approach, the
polymer solution was added at a particular time after initiating the nucleation of the iron
oxide crystals. Following this approach, we obtained polymer-coated nanoparticles with
different sizes, but comparable R2 relaxivities (Table 2). Notably, silica- and PAA-coated
IONP had diameters of 145 and 60 nm respectively, and intriguingly high spin-spin
relaxivities (R2 > 200 mM-1 s-1 ) (Table 2). Therefore, as these nanoparticles have readily
available surface functional groups (amines for silica and carboxylic acid for PAA), their
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conjugation could be facile and allow the formation of MRnS libraries with diverse
probes.

Table 2: Physical prope rties of various preparations of polyme r-coated IONP.
(Dextran: 10 kDa dextran, Silica: tetraethylorthosilicate (TEOS), and PAA: 1.8 kDa
poly(acrylic) acid)

Next, the presence of dextran on the IONP’s surface was confirmed through
clustering experiments with Concanavalin A (Con A). Specifically, the presence of
dextran on nanoparticles can be identified via the Con A- induced nanoparticle clustering,
due to the strong affinity and multivalency of Con A towards carbohydrates, such as
dextran69,

70

. Dynamic light scattering (DLS) experiments revealed a time-dependent

increase in particle size distribution upon Con A addition, due to formation of
nanoparticle assemblies (Figure 2A). Most importantly, a fast and reproducible change in
the T2 relaxation time was observed (Figure 2B), not only indicating the association of
dextran with the nanoparticle, but also hinting the potential use of the dextran-coated rodshaped IONP as magnetic relaxation nanosensors (MRnS). FT-IR experiments (Figure
2C) further confirmed the presence of the characteristic dextran peaks on these
nanoparticles.
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Figure 2: Confirmation of the presence of dextran on IONP.
A) Dynamic-light-scattering-based and B) T2-relaxation-based monitoring of the
Concanavalin A (Con A)- induced clustering of the nanoparticles (200 μL, 2 μg Fe/mL)
after treatment with 10 μL Con A ([Con A]in = 1 μg/μL in 1X PBS). C) Fourier
Transform infrared spectroscopy of dextran and dextran-coated IONP (DION).

One of the most interesting properties of nanomaterials is the enhanced catalytic
activities that some of these materials exhibit. Recently, the peroxidase activity of IONP
has been reported71, 72 . Therefore, we decided to investigate if our IONP possess similar
peroxidase activity. In these experiments, we incubated the IONP (2 μg Fe/ml) with the
peroxidase-sensitive dye 3,3’,5,5’-tetramethylbenzidine (TMB, 0.4 mM), which develops
a blue color upon oxidation in the presence of hydrogen peroxide and a peroxidase.
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Results showed that the dextran-coated IONP possess peroxidase activity as judged by
their ability to oxidize TMB in the presence of hydrogen peroxide within 30 minutes
(Figure 3A). The observed peroxidase activity of the IONP is pH-dependent, as no
oxidation of the dye is observed at pH 7 or even in DMF-water mixtures (Data not
shown). These results are in line with those recently reported, however it is worth
mentioning that our nanoparticles are more magnetic than those previously used71 .
Furthermore, we determined the kinetic parameters of the dextran-coated IONP’s
peroxidase activity, utilizing TMB as the peroxidase substrate. Specifically, a Michaelis
constant, Km of 0.5 mM and a maximal reaction velocity (Vmax ) of 11.6×10-8 M/s were
obtained from the corresponding Lineweaver-Burk plot (Figure 3B). Notably, these
nanoparticles’ Vmax is higher than that of previously reported iron oxide nanoparticles and
horseradish peroxidase (20% and 33% respectively), while having TMB as the
peroxidase substrate71 . Furthermore, their affinity towards TMB is 300 times higher than
that of previously reported nanoparticles, which had a (Km) of ~ 150 mM71 . Taken
together, these data demonstrate the enhanced intrinsic peroxidase activity of our dextrancoated nanoparticles. Subsequently, we investigated if the polymer plays a role in the
IONP’s peroxidase activity, as previous reports demonstrated that the stabilizer or
capping agent affects the physiochemical properties of nanomaterials73,74 . Hence, similar
characterization of the silica- and PAA-coated IONP indicated that these nanoparticles
exhibited peroxidase- mimicking activity, yet with significantly lower Vmax and Km,
suggesting the role of the polymeric coating in the modulation of these parameters (Table
3).
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Figure 3: Pe roxidase-like activity of dextran-coated IONP.
A) Visual confirmation. TMB in citrate buffer (pH 4) was treated with H2 O2 (1) only as a
control, with H2 O2 and dextran IONP (2), and with only dextran IONP and no H2 O2 (3).
(B) Kinetics of peroxidase activity of dextran-coated IONP prepared from a 10 kDa
dextran.

Table 3: Modulation of the IONP’s peroxidase-mimicking activity by the polyme ric
coating.

Polyme ric coating

Vmax (M/s)

Km (mM)

Dextran

12×10-8

0.50

Silica

-8

0.15

-8

0.10

1×10

PAA

4×10
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Conclusion
 We have optimized the stepwise synthesis of various polymer-coated IONP,
including silica- and PAA-coated nanoparticles.
 The nanoparticles exhibited high R2 relaxivities and demonstrated enhanced
peroxidase- mimicking activity, with improved Km outperforming previously
reported iron oxide nanoparticles.
 Silica- and PAA-coated IONP can be used as building blocks for the development
of sensitive MRnS, due to the presence of readily available functional groups on
their surface.
 Dextran-coated IONP may be used as carbohydrate MRnS utilizing their Con Ainduced clustering.

Discussion
Iron-oxide-based magnetic nanoparticles are among the most widely used
nanoparticles in the clinic and the lab. Apart from being used as MRI contrast agents and
effective vehicles in immunoseparation assays, iron oxide nanoparticles have been
recently used as sensitive probes for molecular recognition events. Despite their enhanced
sensitivity and their numerous biodiagnostics applications, little effort has been made to
the optimization of these nanoparticles’ properties. As most contemporary synthetic
protocols utilize an in situ methodology, we hypothesized that an alternative stepwise
approach may facilitate the formation of robust IONP with improved R2 relaxivities and
peroxidase- mimicking activities. Plausibly, a stepwise approach should have facilitated
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the effective nucleation initiation process and uniform crystal growth, which can be
successfully arrested by the addition of the polymer leading to the formation of
monodispersed preparations.
Utilizing a facile, aqueous-based and room temperature stepwise synthesis
protocol, we prepared dextran-, silica- and PAA-coated IONP. The as-synthesized
nanoparticles had different sizes, but all exhibited enhanced R2 relaxivities and
peroxidase- like enzymatic behavior. Hence, this indicates that a stepwise approach is
advantageous over an in situ methodology, primarily due to the improved nanoparticle
formation dynamics that the former method incorporates. Since the silica- and PAAcoated IONP exhibit high R2 relaxivities and carry native functional groups on their
surface, these nanoparticles could be ideal for the formation of MRnS libraries by easily
conjugating biomolecules to the nanoparticles.
Overall, we have demonstrated that application-tailoring of the IONP’s
properties can be modulated by the nanoparticles’ polymeric coating. It is anticipated that
the dextran-coated iron oxide nanoparticles, as well as the other polymer-coated IONP,
may find use in numerous applications, ranging from magnetic-relaxation-based sensing
and diagnostics to hyperthermia, and from MR imaging to catalytic oxidations. Lastly,
the fabrication of devices and nanocomposites with dual magnetic and catalytic activities
is foreseen.
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CHAPTER III: IDENTIFICATION OF BACTERIA VIA
BIOMARKER-SPECIFIC MRnS

Introduction
Bacterial infections are the fifth cause of mortality in the US, and their economic
impact on the industrial, agricultural and healthcare sectors is significant4 . Headlines in
the press about the presence of enterrohemorrhagic E. coli O157:H7 in tainted produce,
the identification of the extremely cytotoxic Subtilase AB5 toxin in E. coli O113:H21, the
aftermath of the B. anthracis attacks in 2001, and the recent identification of drug
resistant Mycobacterium tuberculosis (XDR-TB) in Africa sparked public concern.
Therefore, the need for developing fast, sensitive and reliable detection methods for
bacteria in food, environmental and clinical samples is crucial in order to safeguard
public health. Traditionally, the presence of a bacterium is detected microscopically,
usually after growth in culture. Confirmation is based on growth patterns in various
media and biochemical tests. These methods, although highly specific, have some
drawbacks. First, they usually take more than 24 hours and lack sensitivity due to the
amount of bacteria needed, whereas not all microorganisms can grow in culture. More
recently, other methods involving polymerase chain reaction (PCR) and fluorescent
immunoassays have been developed. However, despite their enhanced sensitivity and
specificity, these methods are costly, time consuming and need to be performed by
trained and experienced personnel. Thus, developing assays for faster and sensitive
identification of bacteria at multiple levels is critical.
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Nanotechnology offers an attractive alternative for the identification of diverse
molecular targets in vitro and in vivo, requiring smaller samples and less preparation
time, without compromising sensitivity

24, 33, 75, 76

. Recently, superparamagnetic iron

oxide nanosensors have been designed to quantify biomolecular targets in cell lysates and
tissue extracts, demonstrating high sensitivity50-52 . The principle underlying the detection
mechanism of these nanosensors is based on their ability to switch from a dispersed to a
clustered (or assembled) state upon target interaction, with a concomitant change in the
spin-spin relaxation time (T2) of the solution’s water protons. Based on changes in T2
(ΔT2) various molecular targets, such as nucleic acids (DNA and mRNA), proteins and
even viruses have been detected. These targets have in common the fact that they are
smaller (e.g. DNA and proteins) or of equal size (e.g. virus) to the nanoparticles.
However, the use of superparamagnetic nanoparticles for the detection of larger
biological targets, such as a bacterium in solution, has not been examined before. We
hypothesized that the presence of multiple bacterial epitopes should compensate for the
size difference between the probe and the target, promoting nanoparticle assembly on the
bacterial surface and consequently resulting in a dose-dependent change in ΔT2 (Figure
4). It was also hypothesized that the lower the number of bacteria in the solution, the
higher the ratio of nanoparticles available to bind and self assemble on the surface of the
bacterium, resulting in higher values of ΔT2 (Figure 4). As the number of bacteria in
solution increases, it was expected that the resulting higher number of bacterial epitopes
will compete with the available number of nanoparticles in solution, therefore causing the
nanoparticles to bind to the bacteria in a more dispersed- like state (Figure 4). Such a
nanoparticle-based bacteria detection system would be highly sensitive, particularly at
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low target concentrations. Also, we reasoned that MRnS, being part of a homogeneous
assay, could be able to detect bacteria at the organism and genomic levels via a single
methodology and instrumentation, without the need of multiple protocols and
instruments. Furthermore, apart from multilevel confirmation, achieving specific and
sensitive detection is critical whenever antibodies cannot differentiate between virulent
and avirulent strains, thus relying on genetic markers. Additionally, the abundance,
stability and quality of epitopes can affect a microorganism’s detection, whereas DNAbased assays have the ability to circumvent these problems, providing important clinical
information usually with lower cost.

Figure 4: Proposed detection mechanism of bacterial targets using spherical
surface-marke r-specific MRnS.
Dispersed nanoparticles in solution self-assemble on the surface of a bacterial target
inducing large changes in T2. As the number of bacteria increases, the number of
nanoparticles interacting per target decreases, resembling a more dispersed- like state with
concomitant smaller changes in T2.
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Materials and Methods
Bacterial cultures, isolates and homogenized tissue.
Lab strains of MAP and clinical isolates were grown in 12B* BACTEC bottles (Becton
Dickinson, Franklin Lake, NJ, USA) as described78 . Quantification of MAP grown in the
BACTEC bottles was assessed with the BACTEC 460 TB Analyzer (Becton Dickinson).
Heat- inactivation of MAP was performed by autoclaving the BACTEC bottle for 10
minutes. Proteus vulgaris #8427, Staphylococcus aureus #33862, Pseudomonas
aeruginosa #27853, Enterococcus faecalis, Escherichia coli #8739, and Serratia
marcescens were grown in culture tubes with nutrient broth, and bacterial growth was
monitored spectrophotometrically. Heat inactivation of these bacteria was performed by
autoclaving the culture tubes for 10 minutes. Upon inactivation, all bacterial stocks were
placed in a Fisher Isotemp freezer (Fisher Scientific, Hampton, NH), until further use.
Clinical isolates and tissue preparations from Johne’s disease and healthy cattle were
prepared and coded by an investigator unaffiliated with this study.

Preparation of MAP MRnS.
The MAP nanosensors were prepared using Protein G-coated magnetic nanoparticles as
described52 . Briefly, the Protein G nanoparticles were incubated with rabbit antiMycobacterium avium spp paratuberculosis (MAP) polyclonal antibody, which was
raised and purified as described in literature79 . Results from preliminary optimization
experiments showed that formation of stable nanoparticle conjugates can be easily
achieved by overnight incubation at 4 o C of 1 μL of antibody with 2 μL nanoparticle
preparation (1.04 mg Fe/mL) in a total volume of 1 mL 1X PBS, pH 8. These nanoprobes
were stable at room temperature and 37 o C, and no precipitation was observed. Whole
30

milk (Velda Farms, Plant #12293, Lakeland, FL) and 2% milk (Publix, Lakeland, FL)
were stored at 0 – 4 o C, and were used prior to their expiration date. Blood from
bacteremia- free Crl:CD(SD)IGSBR female rats (Charles River Laboratories) was stored
at -20 o C. Clinical isolates and animal tissue were treated and handled according to
institutional IRB regulations.

Sample preparation for MAP MRnS.
Serial dilutions of the bacterial stocks were performed after thawing the original stock,
vortexing, and diluting it to the corresponding medium. Aliquots of the nanoparticle
suspension were mixed with the sample in eppendorf tubes, and a micropipette was used
to homogenize. With a Pasteur pipette, the sample was transferred to a relaxometer tube.
The samples were incubated at room temperature or 37 o C while into the relaxometer
tubes. Incubation at 37 o C was performed utilizing an Eppendorf Thermomixer R
(Eppendorf, Westbury, NY). For the specificity assay, 200 μL of nanoprobe solution (2
μg Fe/μL) were incubated with inoculated samples at 37

o

C for 30 minutes.

Quantification of MAP in whole milk was facilitated by incubating 200 μL nanosensors
(2 μg Fe/μL) with inoculated sample at room temperature or 37 o C for 30 and 60 minutes.
Under interference conditions (~109 CFUs non-MAP organisms), MAP was quantified
using MAP-specific nanoparticles (2 μg Fe/μL) and 10 μL inoculated whole milk,
incubated at 37 o C for 30 minutes. T2 measurements were taken immediately or after a
subsequent 45- minute cool-down to room temperature.
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Preparation of IS900-specific MRnS.
The IS900 MRnS were prepared from propargylated PAA-coated iron oxide
nanoparticles, utilizing literature available protocols44 . Conjugation of the azideterminated 15-bp AV1 oligonucleotide (5’-ATGTGGTTGCTGTGT-3’) was achieved via
“click” chemistry, as previously described77 . Briefly, 400 μL propargylated IONP were
resuspended in 1,100 μL NaHCO3 buffer (0.1 M, pH 8.4). To this, we added 200 μL of
10 mM TCEP (tris(2-carboxyethyl)phosphane hydrochloride, Sigma) as a reducing agent.
Twenty μL of 6.3 M AV1 were diluted in 80 μL NaHCO3 buffer (0.1 M, pH 8.4) and
added to the nanoparticle solution. The reaction was initiated with the dropwise addition
of 150 μL Cu(II)-TBTA complex (tris(benzyltriazolylmethyl) amine, 10 mM, Sigma),
which was previously prepared in DI water and t-butanol (9:1). The reaction was
incubated at room temperature under continuous mixing for 3 hours, followed by
overnight incubation at 4 o C under constant mixing. The resulting IS900 MRnS were
dialyzed against DI water using a 6,000 – 8,000 MWCO membrane (Spectrum), followed
by magnetic separation with an LS25 MACS column (Miltenyi). Determination of the
MRnS’s oligonucleotide concentration was achieved by monitoring the absorbance at 260
and 305 nm (background), using a Nanodrop 1000 spectrophotometer (Thermo
Scientific). The MRnS were stored at 4 o C until further use.

Extraction of pure and crude bacterial DNA.
DNA was extracted from cultured bacteria in a class II biosafety cabinet, according to
previously reported procedures78 . One mL of bacterial cultures were aseptically
transferred to microcentrifuge tubes, followed by centrifugation at 13,200 rpms. The
resulting pellets were resuspended in 120 μL sterile TE buffer (10 mM Tris, 1 mM
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EDTA, pH 8.0) and incubated in a dry heat bath at 100 o C. Samples without further
processing were used as crude DNA extracts in MRnS and nPCR studies. In order to
obtain pure bacterial DNA, after heating the samples, we placed them on ice for 15
minutes and then centrifuged them at 12,000 rpm for 10 minutes at 4

o

C. The

supernatants were transferred to Phase- lock gel tubes (Eppendorf), which were
supplemented with 200 μL of phenol/chloroform/isoamyl alcohol (1:1:24 v:v, Acros).
The tubes were centrifuged for 5 minutes (12,000 rpm, 4 o C), and the supernatants were
precipitated using 400 μL 100% ethanol cooled to -20 o C. The precipitated DNA was
washed, dried, and finally reconstituted in 50 μL sterile water. Pure and crude bacterial
DNA was stored at 4 o C until further analysis, whereas spectrophotometric quantification
of DNA content was achieved using a compact spectrophotometer (Nanodrop 1000,
Thermo Scientific). Crude and pure DNA extractions from clinical isolates were similarly
performed.

IS900 MRnS and nested PCR experiments.
Serial dilutions of bacterial DNA were prepared in TE buffer. For the relaxationmediated experiments, 200 μL of the nanoparticle suspension (6 μg Fe/mL in 0.1 M
phosphate buffer, 0.1 M NaCl, pH 7.4) were incubated with 1 μL of bacterial DNA or
control (TE buffer). The samples were heated twice for 3 minutes at 95 o C. After this, the
samples were transferred to relaxometer tubes and let cool down at room temperature,
while taking relaxation measurements using a magnetic relaxometer. For the specificity
assays

using

a

synthetic

target

(AVT,

5’-

TCCTTCGGCCATCCAACACAGCAACCACAT-3’), 1 μL of AVT (1.1 M) was added
to the MRnS mycobacterial samples containing the same DNA concentration (3.5 ng/μL).
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Similar DNA concentration was used for the specificity experiment utilizing other Gram
positive and Gram negative bacteria and MRnS (3 μg Fe/mL). Nested PCR (nPCR) was
performed as previously described78 , where the nPCR for the pure extracted MAP DNA
was performed by an investigator unrelated to the MRnS study (Dr. George Ghobrial).

Measure ment of proton relaxation times.
Spin-spin relaxation times (T2) were measured using a 0.47 T mq20 NMR analyzer
(Minispec, Bruker, Germany). T2 values were obtained before and after addition of the
sample, and through the time course of the study. All experiments and measurements
were carried out in triplicate and data were expressed as mean ± standard error, unless
otherwise denoted. The data were fitted on a sigmoidal curve, using Origin 7.5
(OriginLab, Northampton, MA).

Results
In our studies we used Mycobacterium avium spp. paratuberculosis (MAP), as
our model organism. We selected this bacterium because its growth in culture is difficult
and its identification with current methods is not easy78-81 . In addition, MAP is the known
pathogen causing Johne’s disease in cattle, an economically devastating disease82-84 .
MAP-infected animals show severe intestinal inflammation, which can be degenerative,
and the infection of healthy animals is high, resulting in the herd’s annihilation to prevent
further transmission82-84 . Apart from causing disease in cattle, there is association
between MAP and Crohn’s disease in humans, as this microorganism has been isolated
from the blood, breast milk and intestinal lesions of Crohn’s disease patients78-80,

85

.

Herein, we demonstrate the development of MAP-specific nanosensors that can detect
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MAP at the organism and genomic levels, even in complex media (whole milk and
blood) with high specificity and sensitivity.
First, we prepared antibody-carrying MAP MRnS by conjugating anti-MAP
antibodies79 that recognize MAP surface epitopes to superparamagnetic iron oxide
nanoparticles via Protein G, as described before52 . These antibody-coated nanosensors
were stable for months, after storage at 4 o C. Preliminary studies in phosphate buffered
saline (PBS) demonstrated that the nanosensors responded in a dose-dependent fashion
upon addition of MAP. Formation of the bacterial- induced nanoassembly was detected
upon addition of the bacteria, and this assembly was stable over a 3 hour- long incubation.
For the first set of experiments in complex media, we compared the specificity of our
nanosensors towards MAP, by adding spiked whole milk into 200 μL of MAPnanosensors. The sample that had MAP alone (115 Colony Forming Units [CFUs] in 10
μL) had the highest change in T2, while the samples that had other bacteria (~106 CFUs
in 10 μL) demonstrated minimal T2 changes (Figure 5). More importantly, the sample
containing a mixture of bacteria, including MAP (77.5 CFUs in 10 μL), was identified as
MAP-positive despite the presence of interference, underlying the specificity of our
antibody-carrying nanosensors.
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Figure 5: Specificity of MAP MRnS towards MAP and not other Gram positive and
Gram negative bacteria.
MAP: Mycobacterium avium spp paratuberculosis, E. coli (Escherichia coli), Staph
(Staphylococcus aureus), Pseudomon. (Pseudomonas aeruginosa), Enterococ.
(Enterococcus faeacalis), Proteus (Proteus vulgaris), Serratia (Serratia marcescens) and
Mix (MAP in the presence of the other six non-MAP species 50:50 v/v).

In addition, to verify if the observed changes in T2 were due to antibody- mediated
interactions and not to non-specific nanoparticle aggregation, the bacteria were preincubated overnight with anti-MAP antibody before performing sensing experiments with
the MAP MRnS. Results showed that the ΔΤ2 was abrogated in the bacterial sample preincubated with free MAP antibody (ΔΤ2 = 0.20 ms ± 0.1 ms), due to the inability of the
MAP MRnS to bind to the bacterial epitopes. In contrast, a control bacterial sample that
has not been pre- incubated with MAP antibody had significant T2 changes (ΔΤ2 = 8.90
ms ± 0.3 ms) at the same experimental conditions. To bolster the specificity of the MAP
MRnS, milk samples spiked with 200 CFUs of MAP clinical isolates and other
mycobacteria were screened, obtaining significant T2 changes in the MAP-containing
samples as opposed to the other microorganisms (Figure 6). Furthermore, the T2 of the
MAP MRnS was measured at 25, 30 and 35 o C, without any temperature-dependent
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statistical differences. This implied that the nanoparticles’ performance was steady in
temperatures relevant to those at the points-of-care and that the observed changes in T2
were due to specific antibody- mediated interactions with the MAP bacterium.

Figure 6: Specificity of MAP MRnS towards MAP isolates and not other
mycobacteria.
UCF3, UCF4, UCF5, UCF7 and UCF8 represent different MAP clinical isolates. Myc.
avium: Mycobacterium avium, M. tuberculosis (Mycobacterium tuberculosis), M.
smegmatis (Mycobacterium smegmatis).

Next, we utilized the MAP MRnS for the detection of MAP in milk, as this
bacterium was found in milk from Johne’s disease cattle as well as in the breast milk of
Crohn’s disease patients80 . Detection and quantification of MAP in milk was done by
incubating MAP-spiked whole milk with MAP nanosensors. We found that the change in
T2 was indirectly proportional to the MAP concentration (Figure 7), supporting our
proposed detection model that predicted quasi-dispersion of the MRnS at higher target
concentrations (Figure 4). Reliable quantification of MAP from 15.5 to 775 CFUs
(R2 =0.93) was achieved with the MAP MRnS after a 30- minute incubation at room
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temperature (Figure 7), whereas in control experiments using nanoparticles with no MAP
antibody minimal changes in T2 were observed. It is interesting to note that the MAP
MRnS could identify the bacterium in milk at low CFUs (<15.5 CFUs), even though they
could not quantify it. This offers the ability to assess if a sample is MAP-positive or
MAP-negative at low concentrations (< 15.5 CFUs). Using the same conditions and
setup, MAP was quantified with good correlation in milk at 37 o C. Notably, the described
trend between ΔΤ2 and MAP’s concentration was sustained, even after an hour- long
incubation, regardless of the incubation temperature. Detection and quantification of
MAP was achieved with high sensitivity in 2 % milk as well, after incubation at 37 o C.

Figure 7: Concentration-dependent behavior of MAP-s pecific MRnS in whole milk
at room te mpe rature.

We next investigated if the presence of other bacteria would interfere with
quantification of MAP. In these experiments, we quantified MAP in whole milk and in
38

the presence of six different bacterial species. After a 30-minute incubation at 37 o C, we
were able to determine if a particular sample had the bacteria (MAP positive), and even
determine the actual MAP concentration, having 15.5 CFUs as the assay’s detection limit
under these heavy interference conditions (R2 = 0.86). However, when the incubation was
followed by a 45-minute cool-down to room temperature, the correlation improved (R2 =
0.96), due to the stronger binding and hybridization of the bacterium – nanoparticle
system, yet the detection limit increased to 38.75 CFUs (Figure 8).

Figure 8: Quantification of MAP in whole milk using MAP-specific MRnS under
interference conditions.

Since MAP has been found in the blood of Crohn’s disease patients78 and
bacteremia (presence of bacteria in the blood) is a critical pathological state that requires
fast detection and prompt medical attention, we performed experiments in blood samples.
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In these experiments, we added 20 μL of whole blood containing increasing amounts of
bacteria to 200 μL of the MRnS. Our MAP nanosensors were able to detect and quantify
MAP in a concentration-dependent trend, in accordance to our hypothesis (Figures 9A
and 9B). The assay was sensitive enough to detect MAP after a couple of minutes (Figure
9A), as well as after a 30-minute incubation at 37 o C (Figure 9B), making the assay
relevant to clinical sample conditions.

Figure 9: Quantification of MAP in blood using MAP-specific MRnS.
A) Upon sample preparation and B) after a 30- minute incubation at 37 o C.

In subsequent studies, we utilized the MAP MRnS for the screening of clinical
isolates from Crohn’s disease patients, as well as from two patients with ulcerative colitis
and inflammatory bowel syndrome. In these studies, 10 μL aliquots of the isolates were
added to the MAP MRnS followed by a 30-minute incubation at 37 o C. Interestingly, the
MRnS provided a positive ΔT2 signal for all samples with clinical symptomology,
whereas the sample from a healthy individual exhibited nominal changes in the T2
relaxation times (Figure 10). Independent confirmation of the MAP MRnS findings was
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achieved by performing DNA extraction and nested PCR analysis for the detection of
MAP’s IS900. Hence, these findings are of major clinical importance, as the MAP MRnS
were able to identify the presence of MAP in isolates within just 30 minutes, as opposed
to the 2-day- long DNA extraction followed by a 6-hour-long nested PCR analysis.

Figure 10: Detection of MAP in clinical isolates using MAP-specific MRnS.
Healthy: culture from a healthy individual, IBD: inflammatory bowel disease patient,
CD: Crohn’s disease patients, and MAP (M18): laboratory-cultured MAP serving as
positive control.

Considering the promising MRnS results of clinical isolates and acknowledging
the need for developing reliable methods for bacterial identification in food, we used the
MRnS for the detection of MAP in homogenized tissues from Johne’s disease cattle.
Similar to our previous studies, 10 μL aliquots of various tissues were thoroughly
resuspended in 200 μL of the MAP MRnS followed by a 30-minute incubation at room
temperature. Small, yet reproducible, changes in the T2 relaxation times were recorded in
the various tissues obtained from infected animals (Figure 11A), demonstrating that the
MAP MRnS can quickly detect MAP in environmental and clinically relevant samples
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via a positive/negative assay. To investigate if the 30- minute- long MAP MRnS results
were valid, we performed longer incubations. Notably, after overnight incubation at 4 o C
large changes in the ΔΤ2 were observed, where homogenized lymph nodes, inside and
outside round had comparable levels of MAP as indicated by their similar ΔΤ2s (Figure
11B). The differences in the ΔΤ2 among the various samples after overnight incubation
might be attributed to the fact that either the spatial concentration of MAP differs among
the various tissues due to Johne’s disease pathophysiology or due to the homogenization
protocol not effectively facilitating the release of MAP from its potential intracellular
residence, like macrophages. Overall though, these results indicate that MRnS can be
used for the screening of various samples with minimal or no sample preparation,
preventing epidemics and supporting clinical decision making.
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Figure 11: Detection of MAP in homogenize d tissue from Johne’s disease cattle
using MAP-specific MRnS.
A) After a 30- minute incubation at room temperature the nanosensors identified MAP in
homogenized tissues, but not in ground burger from healthy animals (control). B)
Prominent T2 changed were observed after overnight incubation at 4 o C.
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Figure 12: Synthesis of IS900-specific MRnS for the detection of MAP DNA.
“Click” conjugation of alkyne-functionalized PAA-coated IONP and azide-terminated
AV1 oligonucleotide.

After establishing that the antibody-utilizing MAP MRnS could detect MAP at
the organism level through surface epitope recognition, we prepared MRnS for the
detection of MAP at the genomic level (IS900 MRnS), in order to potentially achieve
multiplexed pathogen identification with even single pathogen sensitivity threshold. To
recognize MAP’s unique genomic IS900 element, the IS900 MRnS were synthesized
using alkyne-carrying PAA-coated IONP as precursors for the “click” conjugation of the
azide-terminated oligonucleotide AV1, which is complementary to IS900 (Figure 12). To
examine the specificity of the IS900 MRnS, we prepared pure DNA extracts from various
mycobacteria, including MAP. Aliquots of the extracts were incubated with the IS900
MRnS for two 3- min incubation rounds at 95

o

C, followed by cooling to room

temperature. Within 30 minutes, results indicated that only samples containing MAP
DNA exhibited a high ΔΤ2 signal, as opposed to the other mycobacterial samples (Figure
13). Interestingly, a mixture of MAP with other bacteria (50:50 v/v), resulting dilution of
the MRnS was also identified as positive, and had a ΔΤ2 that was roughly half the ΔΤ2 of
the sample containing only MAP. This indicates that the IS900 MRnS still exhibit their
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property to alter the solution’s T2 relaxation times in an iron-concentration-dependent
fashion, and are not affected by the presence of complex biomolecules (mycobacterial
DNA). Furthermore, to confirm the specificity of the IS900 MRnS, samples were
incubated with MRnS and excess of a synthetic target (AVT) that was complementary to
the nanoparticles’ AV1 probe. This caused signal abrogation, due to the interaction
between the MRnS and AVT preventing the MRnS – bacterial DNA association (Figure
13).
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Figure 13: Specificity of IS900 MRnS towards MAP and not other mycobacteria.
Pure mycobacterial DNA extracts were subjected to two consecutive 3- minute
incubations at 95 o C with the nanoparticles, followed by cooling at room temperature for
30 minutes. Mixture indicates a sample consisting of MAP DNA and M. tuberculosis/M.
smegmatis 50:50 v/v. In the presence of a synthetic target (AVT) corresponding to a
complementary sequence to AV1, the signal was abrogated.

Often times in clinical and environmental samples other microorganisms might be
found, thus we examined if the IS900 MRnS could differentiate between MAP and some
common Gram positive and Gram negative bacteria. Only the sample containing MAP
yielded a high ΔΤ2, whereas the other bacterial DNA samples exhibited ΔT2 proximal to
that of the sterile control (Figure 14). These data hint the potential use of the IS900
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MRnS at the points-of-interest without requiring extensive sample preparation and
bacterial isolation, due to the high specificity of the IS900 MRnS. Additionally, the
findings that the diluted IS900 MRnS (Figure 14) had comparable ΔΤ2 to that of the
MAP mixture (Figure 13) further confirmed that the MRnS maintained their R2
relaxivity.

Figure 14: Specificity of IS900 MRnS towards MAP and not other Gram positive
and Gram negative bacteria.
TE: TE buffer (Tris:EDTA), and pure DNA extracted from S. aureus (Staphylococcus
aureus), E. faecalis (Enterococcus faeacalis), E. coli (Escherichia coli), P. aeruginosa
(Pseudomonas aeruginosa), P. vulgaris (Proteus vulgaris) and S. marcescens (Serratia
marcescens).
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In subsequent studies, we determined if the IS900 MRnS could quantify MAP
DNA. MAP DNA was isolated using either a 2-day-long extraction protocol or a 30minute boiling-based methodology, yielding pure and crude DNA respectively.
Following incubation and cooling within 30 minutes, both DNA preparations exhibited
concentration-dependent changes in the T2 (Figures 15A-B). Although higher changes
were observed in samples with pure MAP DNA, both DNA extraction methodologies had
equivalent detection thresholds, approaching the low femtogram (10-15 ) regime. We then
examined whether nested PCR (nPCR) can achieve comparable sensitivity, amplifying
crude MAP DNA. After two 3- hour- long cycles and electrophoresis, nPCR was not able
to detect IS900 in samples containing crude MAP DNA (Figure 16). This demonstrates
the sensitivity and robustness of IS900 MRnS to rapidly detect their target even under
conditions of interference, which prevent the use of traditional enzyme-based methods.

Figure 15: Quantification of MAP DNA using the IS900 MRnS.
Α) Pure MAP DNA and B) crude DNA extracted via a 30-minute boiling were quantified
within 30 minutes after two 3- minute- long incubations at 95 o C.
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Figure 16: Inability of nested-PCR (nPCR) to quantify crude MAP DNA.
– Ctrl: negative control (dH2 O) of the first nPCR round, -- Ctrl: negative control (dH2 O)
of the second nPCR round, TE: TE buffer, + Ctrl: two controls of pure extracted MAP
DNA.

In an effort to determine the sensitivity of the IS900 MRnS, we compared MRnS
and nPCR using pure DNA extracts. Also considering the size of MAP’s genome
(4,829,781 bp) and the average molecular weight of a basepair (MW: 650), we calculated
the mass of a single MAP genome copy to be equal to 5.2 fg, and accordingly prepared
serial dilutions of MAP DNA with known genome copy numbers. Using these
calculations, the MAP IS900 MRnS were able to quantify and detect a single copy of
MAP DNA within half an hour (Figure 17A), whereas nPCR was able to detect 5 bacteria
only after the second amplification round (Figure 17B). This translates to a total readout
time for nPCR to more than 6 hours, with the need of more reagents such as primers and
enzymes, as well as labor and equipment time. Intriguingly though, extrapolating the
results of the IS900 MRnS with pure MAP DNA (Figure 17A), one could infer that these
MRnS have similar detection threshold when crude MAP DNA is used (Figures 15A-B).
Overall, these data demonstrate that IS900 MRnS can achieve single MAP genome
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detection even in crude DNA samples, outperforming nPCR in readout time, sensitivity
and robustness.

Figure 17: Comparison of the sensitivity of the IS900 MRnS and nPCR.
A) Single MAP bacterium can be detected with the IS900 MRnS within 30 minutes,
whereas B) comparable sensitivity is achieved after the second nPCR round using pure
MAP DNA. (Upper gel image: first nPCR round, lower gel image: second nPCR round,
N: negative control (dH2 O) and 0: sterile TE buffer).

Finally, encouraged by the previous studies, we screened clinical isolates from
Crohn’s disease patients with the IS900 MRnS and compared our results with nPCR.
Specifically, the DNA used for the relaxation-based measurements was crudely extracted,
whereas for the nPCR pure DNA was used, after establishing that the latter method
cannot utilize crude DNA (Figure 16). Following similar procedures to the
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aforementioned studies, IS900 MRnS were able to rapidly detect MAP in several clinical
isolates (Figure 18A), with good correlation to nPCR (Figure 18B). Based on the
relaxation changes, quantification of MAP can be achieved, whereas the current nPCR
format is not quantitative. Interestingly, one sample deriving from a culture of an ileal
biopsy (GN2’) was identified as positive by the IS900 MRnS, yet negative by nPCR. This
may be justified by either the presence of interferences or poor DNA quality, preventing
nPCR detection. Overall though, these results suggest that IS900 MRnS can be used for
the screening of not only environmental samples, but also clinical ones, significantly
reducing readout time, and eliminating extensive sample preparation steps and the need
for expensive labile reagents.

Figure 18: Screening of clinical isolates using IS900 MRnS.
A) Relaxation- mediated detection of MAP in clinical isolates 30- minutes after crude
DNA extraction, and B) screening and confirmation using nPCR after a two-day DNA
extraction and 7 hours of result readout. All isolates were from blood samples from
Crohn’s disease patients, apart from GN2’ and GN8’ that correspond to ileal biopsies.
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Conclusion
 Anti-MAP antibody-carrying MRnS and IS900 MRnS can specifically identify
MAP, distinguishing it from Gram positive and Gram negative bacteria, as well as
other mycobacteria.
 MRnS can quickly quantify a bacterial target (MAP) in milk and blood with high
sensitivity via magnetic relaxation.
 MRnS can quantify their target under conditions of heavy interference.
 MRnS can rapidly detect MAP in clinical isolates and homogenized tissue
without extensive sample preparation, outperforming current diagnostics
methodologies.

Discussion
Rapid and reliable identification of bacteria is critical. Although microbiological
approaches utilizing antibodies and nucleic acid markers are very sensitive and specific,
their clinical and field application is hindered, as they cannot be performed in crude or
minimally processed samples. For instance, isolation and growth require extensive
methodology that frequently yields results after a couple of days. Thus, clinical decision
making and public healthcare policing are limited, thus delaying proper course of actions,
including treatment and produce recall. Furthermore, apart from being time consuming,
these methods are costly and have to be performed by trained and experienced personnel,
mainly in a laboratory setting.
With the recent advancements in nanotechnology and compact diagnostic
equipment, nanosensors can be devised for the identification of biological targets. Apart
from being sensitive, the use of minute sample volumes with minimum processing, the
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low reagent cost and the faster readout, nanosensors can achieve sensitive detection in
remote areas and at the points-of-care. Among the most promising nanosensors are
MRnS, which were used for the detection of subcellular entities and viruses in complex
media. Little attention has the development of bacterium-specific MRnS received. This
was mainly due to the fact that bacteria are significantly larger than the iron oxide
nanoparticles, potentially causing the nanosensors to be insensitive to a bacterial
recognition event.
Considering this literature gap and the need for sensitive diagnostic modalities in
diverse media, we demonstrated that MRnS can be used for the detection of bacteria in
complex media, such as milk and blood, through magnetic relaxation. Additionally, the
MRnS were able to identify their bacterium target in clinical isolates, achieving
comparable reliability to nested PCR yet obtaining results within a fraction of the time
needed for this method. Notably, homogenized tissues from infected cattle were
identified as MAP positive, hinting the use of the MRnS for food safety monitoring, and
environmental and clinical sample screening..
Furthermore, we achieved fast detection of MAP at the genomic level within half
an hour, using IS900 MRnS. As detection of a pathogen is critical to be achieved in
multiple levels allowing determination of specific biomarkers and virulence factors, we
utilized IS900 MRnS for the quantification of MAP DNA in crude and pure DNA
extracts. The IS900 MRnS were equally sensitive to both DNA preparations, while not
being susceptible to interferences. Single MAP genome copy was detected, surpassing
nPCR in sensitivity and readout time. Moreover, clinical isolates were screened and the
IS900 MRnS had good correlation with nPCR. Based on these findings, the potential use
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of these MRnS in conjunction with other methodologies should be foreseen, allowing
quick assessment of microbial identification and directing treatment routes.
Overall, as the MRnS approach apart from sensitive and fast, it is independent of
the sample’s optical properties, requires minimum sample preparation and can be
performed without extensive end-user training, it will be ideal for point-of-care usage.
Furthermore, these MRnS can be easily adapted for the high-throughput and expedite
screening of samples from animals, humans, and food. Considering the latest
advancements in NMR technology with compact and sensitive instrumentation86 , the
high-throughput and/or portable analysis of multiple samples in complex media should be
doable, even outside of the typical laboratory setting. This method provides a novel
approach for microbial detection that can potentially expedite decision making in a broad
range of fields including the clinical, environmental and agricultural sectors.
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CHAPTER IV: THE ROLE OF NANOPARTICLE VALENCY IN
THE DETECTION OF BIOLOGICAL ENTITIES VIA MRnS

Introduction
The enhanced binding of multiple ligands to a particular cellular target is a
common approach in nature to fine-tune molecular and cellular recognitions with
increased specificity87-96 . This kind of multivalent binding strategy can offer unique
advantages for developing selective and highly sensitive nanoparticle-based diagnostics
and effective therapeutics. Nanoparticles with multiple targeting ligands offer the
advantage of a surface- mediated multivalent affinity, resulting from multiple interactions
between the high local concentration of binding ligands on the nanoparticle’s surface and
epitopes on the corresponding target. In particular, the conjugation of multiple targeting
ligands to iron oxide nanoparticles (IONP) has allowed the creation of multivalent
magnetic relaxation nanosensors (MRnS) for the detection of molecular targets and
events, such as DNA, RNA, proteins, enzymatic activity, small molecule, viruses, and
enzymatic activity50-54 . Detection is achieved by changes in the solution’s water
relaxation times (ΔT2), as these nanosensors self-assemble upon interaction with the
specific target. However, all these cases shared a common target characteristic; the target
was smaller than or had roughly the same size (in the case of a virus) with the
nanosensor. Recently, the detection of a bacterium, a much larger target compared to the
nanosensor, was reported (Chapter III)97 . It was found that the use of a multivalent entity
(bacterium) as a biological target compensated for the size difference between the
nanoprobe and the target, promoting nanoparticle assembly on the bacterial surface with
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concomitant target-concentration-dependent changes in ΔT2. It was speculated that these
differences may have been attributed to the ratio of nanoparticles interacting per target,
hinting that at low bacterial concentrations more nanoparticles self-assembled on the
surface of the bacterium (hence higher ΔΤ2), whereas at high bacterial concentrations
fewer nanoparticles interacted per target to result in lower ΔΤ2.
We hypothesized whether the nanoparticles’ valency may affect the MRnS
detection limit, allowing the engineering of ultrasensitive probes to accommodate a
particular cellular concentration range. We reasoned that nanoparticles with low amounts
of ligand conjugated on their surface (low valency) would assemble on the cell’s surface,
resulting in prominent shifts in the ΔΤ2 (Figure 19A). Αs the cell concentration increases,
the low valency nanoparticles would switch to a quasi-dispersed state, due to their limited
interaction with target moieties on discrete cells, thus causing smaller changes in the ΔΤ2
(Figure 19A). This mechanism would be in line with the reported spherical MRnSmediated detection of bacteria (Mycobacterium avium spp paratuberculosis – MAP)
using IONP conjugated with anti-MAP polyclonal antibodies, where prominent ΔT2 was
observed at low MAP amounts and low ΔΤ2 was recorded at high MAP concentrations97 .
In contrast, we reasoned that high valency nanoparticles should not cluster in the
presence of cells at low concentrations. Instead, the multiple ligands present on the high
valency nanoparticle can interact with several receptors on the cell surface (Figure 19B).
Therefore, the interaction between high valency nanoparticles and cells at low
concentration would result in a less pronounced ΔΤ2, because fewer nanoparticles may
simultaneously interact with multiple receptors on a given cell. Alternatively, as the cell
concentration increases, the probability of high valency nanoparticle binding to surface
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receptors in multiple cells increases. This should facilitate the binding of numerous
ligands on the same nanoparticle with many receptors on different cells, causing
extensive clustering of the nanoparticles and an increase in ΔΤ2 as the number of cells
increases. (Figure 19B).

Figure 19: MRnS’s valency facilitates distinct magnetic relaxation sensing trends.
A) At low target concentrations, nanoparticles with low valency readily assemble on the
target and cause large shifts in the ΔΤ2, whereas B) fewer nanoparticles with high
valency interact per target resulting in lower ΔΤ2. At high target concentrations, the
nanoparticles with A) low valency switch to a dispersed- like state with a concomitant
ΔΤ2 reduction, but B) the ones with high valency bind and cluster between multiple
targets, facilitating prominent ΔΤ2 changes.
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Hence, the lack of a comprehensive study addressing how multivalency affects
the nanoparticles’ cell surface assembly (e.g. bacterium or cell) and the corresponding
MRnS response prompted us to utilize MRnS with engineered valency towards the
detection of cancer cells in blood samples. We selected cancer cells as a model target,
because it has been recently reported that viable tumor-derived epithelial cells found in
circulation (circulating tumor cells) are a novel class of cancer biomarkers, participating
in the initiation of the process of metastasis98-100 . Current molecular diagnostic techniques
cannot detect low concentrations of cells in biological media (i.e. blood)100 , because of
the matrix’s optical properties and complexity. Furthermore, commonly used cytological
and immunocytochemical techniques require the cell’s isolation, purification, fixation
and quantification using fluorescent probes and microscopic examination, which prevent
propagation of the cells for further analyses101,
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. All of the above highlight the

importance of developing nondestructive methods for the sensitive detection of
circulating tumor cells in blood samples. For our studies, we decided to use a small
molecule as opposed to an antibody, because its small size could guarantee higher
nanoparticle multivalency and its stability would lead to the development of robust fielddeployable nanosensors that are not susceptible to thermal denaturation. As a model
small molecule ligand, we chose folic acid (folate), which is the canonical affinity ligand
of the folate receptor (FR) that is overexpressed in some tumor cells103 . Although
circulating tumor cells more prevalently overexpress other cell surface markers, such as
EpCAM99 , recent studies indicate that the folate receptor (FR) is overexpressed in
numerous cancers, including ovarian, testicular, breast and lung103 . Furthermore, as the
expression of FR is upregulated during metastasis, this receptor is a good marker for
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diagnosis, targeted imaging and drug delivery. As our cellular target, we used A549 lung
cancer cells, because lung cancer is among the most common sites of origin of metastatic
cancer through migration of lung cancer cells via the circulation104 , and this cell line is
known to overexpress the folate receptor103 . Therefore, we investigated if the folate
nanoparticle preparations, and particularly the high- folate ones, can be used for the
quantification and sensitive detection of single FR-expressing A549 cells in complex
media, via magnetic relaxation.

Materials and Methods
Reagents.
All reagents were of AR (Analytical Reagent) grade. Iron salts (FeCl2 .4H2 O and
FeCl3 .6H2 O) were obtained from Fluka. Polyacrylic acid (MW 1.8 kDa), ammonium
hydroxide, hydrochloric acid, folic acid, N, N’-dimethylformamide (DMF), Nhydroxysuccinimide (NHS), cholera toxin B subunit (Ctb) and 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich. The
dialkylcarbocyanine fluorophore DiI (D282) and the nuclear stain DAPI (4', 6-diamidino2-phenylindole – D1306) were purchased from Invitrogen. EDC (1-Ethyl-3-[3dimethylaminopropyl] carbodiimide hydrochloride) and Protein G were obtained from
Pierce Biotechnology, whereas the polyclonal rabbit anti-human folate receptor antibody
(FL-257) was purchased from Santa Cruz Biotechnology. The polyclonal anti-MAP
antibody was a gift from Dr. Saleh Naser (Burnett School of Biomedical Sciences,
College of Medicine, UCF).
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Synthesis of propargylated polyacrylic-acid-coated iron oxide nanoparticles.
The polyacrylic-acid-coated iron oxide nanoparticles were synthesized using the alkaline
precipitation method, as recently reported44 . Briefly, the nanoparticles were prepared by
rapidly mixing a Fe+3 /Fe+2 solution with an ammonium hydroxide solution for 30
seconds, before adding the polyacrylic acid (PAA) solution. The nanoparticles were
washed, concentrated and finally reconstituted in phosphate buffered saline (pH = 7.4),
using a KrosFlo Research II TFF system equipped with a 10 kDa column (Spectrum
Labs). Propargylation of the as synthesized nanoparticles was achieved with
carbodiimide chemistry, as previously reported44 . The propargylated nanoparticles were
magnetically separated and characterized, following published protocols44 .

Synthesis of folate-carrying MRnS with different nanoparticle valency using “click”
chemistry.
To synthesize folate-conjugated nanoparticles, propargylated nanoparticles (13 mg, 1.69
mg/mL) were added to azide- functionalized folic acid (folate~N 3 ), according to the
literature44 . Different levels of nanoparticle valency were achieved by varying the
stoichiometric ratio of nanoparticle ligand to nanoparticle concentration. For the
preparation of low-folate nanoparticles, 0.4 μg of folic acid (0.8 × 10-2 μmol) were used,
whereas for the high- folate nanoparticles 4 mg (8 × 10-2 mmol) of folic acid in DMSO.
The reaction was initiated at room temperature in the presence of catalytic amount of CuI
(0.01 µg, 0.6 x 10-10 mmol), in 125 µL of bicarbonate buffer (pH 8.5), and further
incubated for 12 h at room temperature (“click” chemistry). The final reaction mixture
was purified with a magnetic column, and finally dialyzed using a 6,000 – 8,000 MW
cutoff dialysis bag, against deionized water and phosphate buffered saline (PBS). The
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folate nanoparticle preparations were stored at 4 o C until further use. Confirmation of the
successful conjugation of folate to the nanoparticles was achieved through UV-Vis and
fluorescence emission spectroscopy. In order to make our nanoparticles multimodal, we
loaded them with a lipophilic fluorophore. Dye-doped folate-conjugated iron oxide
nanoparticles were prepared by the drop-wise addition of DiI (0.1 μg/μL in DMF) in 4.5
mL of the nanoparticle suspension ([Fe] = 1.69 mg/mL), as described in literature44 . The
nanoparticles were magnetically separated, and the complete removal of free (nonencapsulated) dye was confirmed through fluorescence emission spectroscopy,
demonstrating a single red-shifted emission maximum. Finally, the nanoparticles were
stored in dark at 4 o C until further use.

Synthesis of antibody-carrying MRnS with different nanoparticle valency.
For the conjugation of Protein G to the nanoparticles, polyacrylic-acid-coated
nanoparticles ([Fe] = 0.25 mg/mL) were taken in 2 mL MES buffer (pH = 6), and to this
we added EDC (1 mg, 0.11 mmol) and NHS (0.8 mg, 0.15 mmol). This reaction mixture
was incubated for 3 minutes, followed by drop-wise addition of Protein G (1.5 mg, 60
μmol) in DI water (0.5 mL). Next, the solution was incubated for 30 min at room
temperature under continuous mixing, followed by overnight incubation at 4 o C. In order
to remove any Protein G molecules that did not conjugate to the nanoparticles, we
performed magnetic separation using a 1X-PBS-equilibrated LS25 column. Protein
quantification revealed that the nanoparticle preparation’s Protein G concentration was
0.1 μg/μL. Subsequently, we conjugated either anti-FR or anti-MAP antibodies to the
Protein G-carrying nanoparticles, as previously reported52 . However, in order to engineer
the nanoparticle valency, the Protein G nanoparticles (250 μ L) were incubated with
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different antibody amounts (5 μg anti-FR, 0.5 ng anti-FR, 5 μg anti-MAP or 0.5 ng antiMAP), yielding either anti-FR or anti-MAP MRnS with different degrees of valency,
which was assessed in accordance to the literature105, 106 .

Synthesis of dextran-coated and galactose-carrying MRnS preparations.
Dextran-coated MRnS were prepared as previously reported107 . Aminated PAA-coated
IONP were synthesized in accordance to the literature44 , and conjugation of
galactopyranosyl nonanoic acid (Toronto Research Chemicals) was achieved via
carbodiimide chemistry. Specifically, 1,000 μL of aminated PAA-coated IONP ([Fe] =
2.5 μg/μL) were reacted with the carboxylated galactose (33 mg in 1,000 μL DI water –
DMSO 50:50 v:v) in the presence of EDC and NHS (9.5 and 5.5 mg respectively in 1,000
μL MES buffer). The reaction was carried out overnight at 4 o C under constant mixing,
followed by dialysis (6,000 – 8,000 MWCO) and magnetic separation.

Nanoparticle characte rization.
The size of the folate-conjugated MRnS was determined through dynamic light scattering
(DLS), using a PDDLS CoolBatch 40T instrument and the Precision Deconvolve 32
software. Iron concentration was determined spectrophotometrically after acid digestion
of the nanoparticles’ suspension as previously reported44,
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, whereas R1 and R2

relaxivity measurements were obtained using a 0.47T mq20 NMR analyzer (Minispec,
Bruker). Zeta potential measurements were performed on a Nano-Z zetasizer (Malvern),
operating at 25 o C. To determine the presence of propargyl groups on the surface of the
propargylated nanoparticles, FT-IR was performed on a PerkinElmer Spectrum 100 FTIR spectrometer, and to confirm the successful conjugation of folate to the folate
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nanoparticles’ surface UV-Vis absorbance and fluorescence emission profiles were
obtained, using a Cary300 spectrophotometer (Varian) and a NanoLog-3 fluorimeter
(Horiba Jobin- Yvon). Similarly, the folate nanoparticles’ fluorescence emission
associated with the encapsulated DiI was determined with the NanoLog-3 fluorimeter.
Protein G and antibody quantification was achieved colorimetrically through the BCA
assay (Pierce) in accordance to the supplier’s protocol, and determination of the amount
of folate and antibody per nanoparticle was determined as described in literature 52, 105, 106 .

Mammalian cell cultures.
Cancer human alveolar cells (A549) and normal (non-cancer) rat cardiomyocytes (H9c2)
were obtained from ATCC, and maintained in accordance to the supplier’s protocols.
Briefly, the A549 cells were maintained in a 5%-FBS-containing DMEM medium
supplemented with antimycotic/antibiotic, whereas the H9c2 cells were propagated in a
10%-FBS-containing MEM medium containing antimycotic/antibiotic. All cell cultures
were grown in a humidified incubator at 37 o C under a 5% CO 2 atmosphere.
Hemocytometer-mediated cell quantification.
After detaching the cells from the culture plate using trypsin and suspending them in
growing medium, the cellular suspension was centrifuged at 1,000 rpm for 8 minutes and
the pellet was re-suspended in 2 mL of the corresponding medium. Ten μL aliquots of the
resulting cell suspensions were thoroughly mixed with 10 μL trypan blue solutions.
Quantification was performed using a hemocytometer and a phase-contrast microscope.
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Serial dilutions of stock mammalian cellular suspensions.
After determining the cell concentration of the stock suspensions, serial dilutions were
prepared in 1X PBS, 5% PBS-diluted blood or whole blood, using aseptic techniques.
Fresh blood was a gift from Dr. James Hickman (UCF NSTC), obtained from
bacteremia- free Crl:CD(SD)IGSBR female rats (Charles River Laboratories). All serial
diluted samples were used immediately after preparation.

Fluorimetry-based determination of MRnS – mammalian cell association.
One mL cellular suspensions (103 and 106 A549 cells) in PBS, were incubated with 1 μL
folate-carrying nanoparticles ([Fe] = 1.69 μg/mL) for 60 minutes at room temperature,
under continuous mixing (300 rpm). To remove any unbound nanoparticles, the samples
were centrifuged three times at 1,000 rpm for 8 minutes, each centrifugation round
followed by washing with 1X PBS. The resulting cell pellets were resuspended in 1 mL
1X PBS, and fluorescence emission spectra were recorded using a NanoLog-3
fluorimeter (Horiba Jobin-Yvon).

Confocal laser-scanning microscopy.
A549 cells were grown overnight on culture dishes, before treatment. After incubation
with the nanoparticles, the cells were washed three times with 1X PBS, fixed with 5%
formalin solution, and stained with DAPI (Molecular Probes). Subsequently, the cells
were examined with a Zeiss LSM 510 confocal microscope equipped with a 40X
objective.
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Dynamic light scatte ring (DLS) of MRnS – mammalian cells.
One mL cellular suspensions in PBS, either with 103 or 106 A549 cells, were incubated
with 1 μL folate-PAA-IONP ([Fe] = 1.69 μg/mL) for 60 minutes at room temperature,
under continuous mixing (300 rpm). The alterations in the nanoparticle size distribution
were monitored through the PDDLS CoolBatch 40T instrument and the Precision
Deconvolve 32 software.

Magnetic-relaxation-mediated mammalian cell detection.
Ten μL aliquots of cell suspensions were incubated with 190 μL of nanoparticle working
solutions ([Fe] = 0.01 μg/μL) at room temperature. Spin-spin relaxation times (T2) were
recorded over time via the 0.47T mq20 NMR analyzer (Minispec, Bruker, Germany),
operating at 40 o C.

Magnetic isolation of A549 cells and detection of the expression of the folate
receptor.
After screening samples via magnetic relaxation, they were incubated with various
concentrations of folate-PAA-IONP for 30 minutes at 37 o C. Subsequently, each sample
was passed through a 1X-PBS-equilibrated LS25 MACS® column (Miltenyi Biotec).
After removing the column from the magnet, the eluate was captured in culture dishes
with 5%-FBS-containing DMEM medium. The dishes were placed in a humidified
incubator (37 o C, 5% CO2 ) for 24 h, as according to the supplier the doubling time of
A549 cells is 18 h. Then, the cells were washed three times with 1X PBS and fresh
medium was added. Cells were quantified using the hemocytometer method and 500-cell
aliquots of either A549 or H9c2 cells were seeded into a 96-well microtiter plate. After
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overnight growth, the cells were incubated for 1 h with different nanoparticle
concentrations at 4 o C. Then, the cells were washed three times with 1X PBS in order to
remove any unbound nanoparticles, and 100 μL of 0.2 mM TMB in citrate buffer pH 4.0
(3, 3’, 5, 5’-tetramethylbenzidine, Sigma) as well as 10 μL H2 O2 (Acros) were added.
Twenty minutes after, absorbance was recorded at 652 nm, using a μQuant 200 microtiter
plate reader (Biotek).

Flow cytometry.
A549 and H9c2 cells were grown until reaching confluence. After detachment and
centrifugation at 1000 rpm, the cell pellets were collected and resuspended in 1X PBS.
The resulting cell suspensions were incubated with the anti- folate-receptor antibody (0.5
μg/mL) for 30 min at 4 o C, under continuous mixing. After the incubation with the
primary antibody, the cells were centrifuged and resuspended in PBS three times,
followed by a 30-min incubation at 4 o C with an FITC-conjugated goat anti-rabbit-IgG
antibody (0.5 μg/mL). The FITC-conjugated antibody was a gift from Dr. James
Hickman (Nanoscience Technology Center, UCF). Finally, the cells were centrifuged and
resuspended in PBS three times, and the cellular suspensions were examined using a
FACSCalibur flow cytometer (BD Biosciences).

Cell viability studies.
Equal populations of A549 cells either magnetically isolated using the folate-carrying
iron oxide nanoparticles or readily harvested, which had been quantified with a
hemocytometer, were seeded in 96-well plates. After overnight growth in a 5%-FBScontaining DMEM medium at 37 o C, 5% CO2 in a humidified incubator, the cells were
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washed three times with 1X PBS and treated with 20 μl MTT (5 μg/μl, Sigma-Aldrich )
for 2 hours. Using acidified isopropanol (0.1 N HCl), the formazan crystals were
dissolved and the absorbance was recoded at 570 nm and 750 nm (background) via a
Synergy μQuant microtiter plate reader (Biotek).

Bacterial stocks.
Serial dilutions of heat inactivated Mycobacterium avium spp. paratuberculosis (MAP) in
1X PBS and anti-MAP antibody were a gift from Dr. Saleh Naser (Burnett School of
Biomedical Sciences, College of Medicine, UCF).

Magnetic-relaxation-mediated bacterial cell detection.
Similar to the mammalian cell (A549) protocol, ten μL aliquots of cell suspensions were
incubated with 190 μL of nanoparticle working solutions ([Fe] = 0.01 μg/μL) at room
temperature. Spin-spin relaxation times (T2) were recorded over time via the 0.47T mq20
NMR analyzer (Minispec, Bruker).

Dynamic light scatte ring (DLS) of MRnS – bacteria.
Similar to the corresponding mammalian studies, one mL MAP bacterial suspensions in
PBS, either with 500 or 5 CFUs (Colony Forming Units), were incubated with 1 μ L antiMAP-PAA-IONP ([Fe] = 0.50 μg/mL) for 60 minutes at room temperature, under
continuous mixing (300 rpm). The alterations in the nanoparticle size distribution were
monitored through the PDDLS CoolBatch 40T instrument and the Precision Deconvolve
32 software.
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Surface Plasmon Resonance (SPR) studies for the toxin-sensing MRnS.
GM1-coated slides were prepared by applying 50 μL of the ganglioside (3 ng/μL, Sigma)
directly to the apical surface of the gold plate. The plate was allowed to air dry for 30
minutes at room temperature. Afterwards, the Ctb pentamer was appended to the GM1coated SPR sensor slide by diluting 2 μL Ctb (1 μg/μL, Sigma) to 50 μL 1X PBST
(Phosphate buffered Saline Tween-20, Fisher), and the slide was stored at 4 o C until
further use. The SPR experiments were performed on a Reichert SR7000 SPR
refractometer (Depew, NY). Before adding the experimental samples, PBST (pH 7.4)
was perfused over the sensor slide for 5 minutes, in order to establish a baseline reading.
The samples, diluted accordingly to 1X PBST, were then flowed over the sensor slide,
where the potential ligand binding to the toxin-coated sensor slide led to an increase in
the mass on the slide. Subsequently, this shift in mass generated a change in the
resonance angle of the reflected light, which was recorded as a change in the refractive
index. After each reading, the bound ligand was removed from the sensor slide by PBST
washing for 5 minutes. The SPR studies were based on a blind setup, hence performed by
an investigator unrelated to the MRnS study (Dr. Tuhina Banerjee).

Magnetic-relaxation-mediated detection of the Cholera toxin B subunit (Ctb).
Serial dilutions of Ctb were prepared in DI water. Five μ L aliquots of Ctb were incubated
with 195 μL of either galactose-carrying or dextran-coated MRnS working solutions ([Fe]
= 0.001 μg/μL) at room temperature. Spin-spin relaxation times (T2) were recorded over
time via the 0.47T mq20 NMR analyzer (Minispec, Bruker).
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Data analysis.
All experiments were performed at least three times, and during each experiment three
measurements were taken for each experimental condition. Each graph dataset contains
the obtained averages of the corresponding study. Total fluorescence intensity per mL
(Total FImL) is defined as the summation of each 1- mL sample’s fluorescence intensities
from 570 to 640 nm. For the magnetic relaxation quantification plots, the best model fit
was achieved using either linear or sigmoidal fit (OriginPro 7.5, Origin Lab Corp, MA,
USA). As we previously reported, ΔΤ2 is defined as the average T2sample,i minus the
average T2control,i at time i, where for the control sample sterile, non-spiked medium
(blood or milk) was used. To determine cell viability, we subtracted the background
absorbance at 750 nm from the absorbance at 570 nm, as previously reported. The
percentage cell viability for the cells isolated was calculated using the formula: ΔA570750sample/ΔA570-750control

× 100, where the corresponding control for the cells isolated with

low- and high- folate nanoparticles were harvested cells seeded in low and high
population counts (Control low and Control high).

Results
To examine our hypothesis, we prepared polyacrylic-acid-coated iron oxide
nanoparticles with different ligand valency by varying the stoichiometry of the
conjugation reaction. These polymer-coated nanoparticles had an average hydrodynamic
diameter of 90 nm, ζ potential of -82.6 ± 2.4 mV, spin- lattice (R1) and spin-spin
relaxations (R2) of 53 mM-1 s-1 and 206 mM-1 s-1 , respectively. “Click” conjugation of
targeting moieties to the nanoparticles’ surface was achieved by incorporating alkyne
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groups via carbodiimide chemistry (Figures 20 and 21), having a ζ potential of -62.6 ±
2.9 mV.
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Figure 20: Schematic representation of the surface modification and folate
conjugation to polyacrylic-acid-coated IONP.

Figure 21: FT-IR spectra of the unmodified and alkyne-modified polyacrylic-acidcoated IONP.
IONP-PAA: unmodified PAA-coated IONP; IONP-PAA-C2: alkyne- modified PAAIONP

As a model targeting moiety, we used folic acid (MW: 441.4), which is the
affinity ligand of the transmembrane folic acid receptor (FR) that is overexpressed in
several cancers103 . Hence, azide- functionalized folic acid was conjugated to the alkynecarrying polyacrylic-acid-coated nanoparticles via click chemistry, having different
concentrations of folate while maintaining constant the nanoparticle concentration. The
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presence of folate on the nanoparticles was corroborated by the presence of a 352 nm
shoulder peak in the UV-Vis absorbance spectrum (Figure 22A) and a corresponding 446
nm peak

in the

fluorescence emission spectrum (Figure 22B). Using

this

spectrophotometric information and following published protocols105, 106 , we determined
that the high- folate nanoparticles had on average 120 folic acid moieties per nanoparticle
(ζ potential = -59.4 ± 3.6 mV), whereas the low- folate nanoparticles had on average 1
folic acid per nanoparticle (ζ potential = -53.5 ± 4.1 mV).

Figure 22: Spectroscopic characte rization of the folate-carrying MRnS.
A) UV/Vis and B) fluorescence emission spectroscopy.

The folate-carrying nanoparticles were then doped with the fluorophore (DiI),
resulting in fluorescently labeled nanoparticles (Figure 23), as recently reported44 .
Contrary to fluorophore conjugation to the nanoparticles’ surface, this method facilitates
fluorophore encapsulation within the polymeric coating’s microdomains and does not
compromise the nanoparticles’ folic acid valency. Hence, this allows the use of these
nanoparticles in confocal microscopy (Figure 24) and fluorimetric studies with folatereceptor-expressing cells (Figure 25).
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Figure 23: Fluorescence emission spectrum of the multimodal DiI-encapsulating
folate MRnS.

Figure 24: Confocal laser-scanning microscopy indicating the association of DiIencapsulating folate IONP with FR-expressing cells.
A549 cells; Red: DiI, Blue: DAPI
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In addition to the folate nanoparticles that carry a small molecule (folate), we
synthesized nanoparticles with different levels of anti- folate-receptor (anti-FR) antibodies
(MW: 150,000). Specifically, via carbodiimide chemistry, Protein G was conjugated to
the as synthesized polyacrylic-acid-coated nanoparticles, which have readily available
carboxylic acid groups. Following magnetic separation and nanoparticle-associated
protein quantification (2 Protein G molecules per nanoparticle on average), the antibodies
were conjugated to the Protein G nanoparticles through an overnight reaction carried at 4
o

C. To engineer the valency and obtain nanoparticles with either low or high levels of

conjugated antibodies, we varied the stoichiometry of the nanoparticle conjugation
reaction, by modifying one of the reactant’s concentration (either 5 μg anti-FR or 0.5 ng
anti-FR) while keeping the Protein G nanoparticles’ amount constant (250 μL). These
conjugation reactions resulted in the formation of nanoparticles with high (4 anti-FR
molecules per nanoparticle on average) and low (1 anti-FR molecule per nanoparticle on
average) anti-FR levels, as determined with the BCA assay following literature available
protocols.
To initially test our hypothesis, we investigated the MRnS – cell associations via
fluorescence spectroscopy. Since our nanoparticles apart from magnetic are fluorescent,
we employed this technique due to its enhanced sensitivity and spectral acquisition
capability, allowing the determination of the nanoparticle – cell association and
quantification of this interaction by recording the fluorescence emission from the isolated
cells. Therefore, any fluorescence emission associated with the isolated cells should have
been an indication of the degree of interaction between the nanoparticles’ ligands and cell
surface receptors. A major advantage of fluorescence spectroscopy in contrast to confocal
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laser scanning microscopy is its ability to determine the cell – nanoparticle interaction in
suspension, where confocal microscopy requires adherent cells. Additionally, although
flow cytometry is an alternative solution-based technique, it was not employed because
(i) large cell populations are required to obtain statistically significant results, (ii) it has
limited sensitivity for fluorophores that weakly associate with cells or at low fluorophore
concentrations (for instance few nanoparticles), and (iii) the compromised multispectral
capability (restricted number of acquired wavelengths).
Thus for the fluorimetry studies, the two nanoparticle preparations having
different folate levels (120 versus 1 folate molecule per nanoparticle) were incubated for
1 h at room temperature under constant mixing with folate-receptor-expressing lung
carcinoma cells (A549) in suspension103 , followed by cell harvesting via centrifugation.
The resulting cell pellets were washed with 1X PBS to remove any unbound
nanoparticles and finally reconstituted in 1 mL 1X PBS, allowing the comparison of total
fluorescence emission per mL (Total FImL) among the various samples. Interestingly,
fluorimetry studies revealed that the total fluorescence emission from the low cell density
sample incubated with low- folate nanoparticles was higher than that of the corresponding
high cell density sample (Figures 25A and 25B). This difference may be attributed to the
higher number of recognizable epitopes in the cell suspension, as a result of the higher
cell density (more cells more folate receptors), mediating MRnS’s quasi-dispersion with a
concomitant reduction in cell- associated fluorescence.
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Figure 25: Distinct associations between fluorescent-labeled folate IONP and FRexpressing cells due to the nanoparticles’ different valency.
A) Low and B) high cell density A549 cells incubated with DiI-encapsulating low-folate
nanoparticles. C) Low and D) high cell density A549 cells incubated with the
corresponding high- folate nanoparticles. (The two primary fluorescence emission peaks
for DiI are indicated, as well as the total fluorescence emission per mL (Total FImL) of the
acquired spectra. Insets diagrammatically represent the interactions between cells and the
nanoparticles in equal- volume samples.)

Likewise, we assessed the high- folate MRnS interaction with A549 cells, by
employing the same experimental approach. Contrary to what was observed with the lowfolate nanoparticles, fluorimetry studies demonstrated that under conditions of low cell
density the total fluorescence emission was lower than that from the high cell density
sample (Figures 25C and 25D). It is plausible that at low cell density the nanoparticles’
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higher valency may have facilitated the interaction of a given nanoparticle with multiple
folate receptors found on the same cell. Consequently, this may have caused fewer highfolate nanoparticles interacting with a given cell, leading to less prominent cell- associated
fluorescence. However, under high cell density, the high- folate nanoparticles
multivalency could have promoted the nanoparticle’s inter-cellular interaction with folate
receptor epitopes found on adjacent cells in the nanoparticle’s proximity, leading to
enhanced fluorescence emission.
To further assess the interaction between MRnS and cells, DLS was used to
determine how the nanoparticle valency differentially mediates the dispersion state of the
nanoparticles in solution under varying target cancer cell concentrations. In the absence
of any cell in solution, the nanoparticles were highly dispersed as 100% of the
nanoparticles had a diameter below 100 nm, as previously reported.44 When the low
folate nanoparticles were added to a suspension of cells at low cell density (103 A549
cells/mL), 23% of these nanoparticles formed large nanoparticle aggregates while only
77% remained dispersed (Table 4). In contrast, only 14% of the high- folate nanoparticles
formed nanoparticle aggregates at the same cell density (103 A549 cells/mL), in
accordance with our hypothesis (Table 4). As stated before, this may be attributed to the
fact that the high- folate nanoparticles’ increased valency can facilitate the interaction of a
nanoparticle with multiple target receptors on the same cell, similar to what was observed
through fluorescence spectroscopy (Figure 25C). Interestingly, when we increased the
number of cells in suspension to 106 cells/mL, the population of low-folate nanoparticles
adopting a clustered state decreased from 23% to 13%, whereas the population of
clustered high- folate nanoparticles increased from 14% to 35% (Table 4). These changes
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are in line with the fluorimetry data, where similar changes were observed. Specifically,
for the low- folate nanoparticles, DLS indicated a reduction by a factor of 1.77 versus
1.63 by fluorescence spectroscopy, whereas for the high- folate nanoparticles both
methods provided comparable results (DLS increase by a factor of 2.5 vs 2.43 determined
by fluorimetry). Taken together, the fluorimetry and dynamic light scattering results
corroborate our model, and demonstrate that the nanoparticles’ ligand valency modulates
the differential interactions between folate MRnS. Hence, these distinct nanoparticle –
cell associations in solution may facilitate different magnetic relaxation sensing dynamics
and cell capturing capabilities.

Table 4: Size distribution of the folate nanoparticles in the presence of various A549
concentrations.
(Means ± SE)
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Considering that detection with MRnS is governed by the degree of nanoparticle
association50, 52 with a target and in light of the aforementioned data, we reasoned that
there could be dramatic differences in the magnetic-relaxation- mediated cell detection,
attributed to the nanoparticles’ valency. We anticipated that MRnS with high valency,
due to the multiple specific interactions between their carrying ligands and cell epitopes,
may achieve better detection sensitivity and even single cancer cell quantification. This is
critical, as it was recently demonstrated that even a single metastatic cancer progenitor
cell can successfully induce tumor formation108 .
Specifically, we utilized the folate MRnS preparations (1 versus 120 folate
moieties per nanoparticle) and the anti-FR ones (1 versus 4 antibody molecules per
nanoparticle), in order to assess the detection performance of these nanosensors. To
demonstrate the potential ability of our nanosensors to detect circulating cancer cells in
clinical samples, we detected A549 cells in blood diluted in phosphate buffered saline
(PBS). In these studies, a stock cellular suspension of A549 cells was quantified using a
hemocytometer, followed by the preparation of serial dilutions of the stock suspension in
PBS-diluted blood. Subsequently, 10 μL aliquots of the resulting cellular suspensions
were incubated with 190 μL of the corresponding nanoparticle working solution ([Fe] =
0.01 μg/μL) at room temperature, while monitoring the changes in spin-spin relaxation
(ΔΤ2) with a magnetic relaxometer operating at 0.47 T.
After a brief 1- hour- long incubation at room temperature under continuous
mixing, distinct valency-dependent trends were observed (Figure 26A-D). We chose 1hour- long incubation at room temperature in order to investigate the field applicability of
our assay and its ability to provide fast and reliable results, whereas mixing of the
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samples minimized the possibility of nanoparticle internalization via folate-receptormediated endocytic uptake. An increase in the ΔΤ2 was observed as the number of A549
lung carcinoma cells increased in solution when both high valency nanoparticles (high
folate and high ant-FR antibody) were used (Figures 26A-B), whereas the opposite trend
was observed for the nanoparticles with low ligand levels on their surface (decrease in
ΔΤ2 when the cell concentration increased) (Figures 26C-D). These results supported our
hypothesis and were in line with the DLS and fluorimetry data. Specifically, as the ΔΤ2
for high cell counts (>1000) of the low-folate nanoparticles was 1.5 – 1.7 ms and the ΔΤ2
for a single cell detected by the high- folate nanoparticles was 2.5 ms, this may be
attributed to the fact that 13% of the low folate nanoparticles interacted with cells at high
cell density versus 14% of the high valency nanoparticles associated with cells at low cell
density, as determined through DLS (Table 4).

79

Figure 26: Relaxation-mediated detection of cancer cells in PBS-diluted blood after
a 60-min incubation.
A) Using high- folate nanoparticles, B) high-anti-FR nanoparticles, C) low-folate
nanoparticles and D) low-anti-FR nanoparticles. (Means ± SE; SE were within 1-2%,
which are too small to be depicted)

Furthermore, our data suggest that in our previous report97 the observed decrease
in ΔΤ2 upon increase of the bacteria concentration was attributed to the nanoparticles’
low antibody levels (low nanoparticle valency). This is corroborated by the detection
pattern of the low-anti-FR nanoparticles (Figure 26D), exhibiting sigmoidal shape similar
to our previous report using MAP bacteria and a corresponding low valency
nanoparticle97 . Although the detection threshold of the low valency anti-FR nanoparticles
was 104 cells, the low- folate nanoparticles were more sensitive and able to detect a single
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cell and quantify the target within the range of 1 to 103 cells, (Figure 26C). Most
importantly, the high- folate nanoparticles were able to detect and quantify cells within an
even wider dynamic range (1 – 106 ) (Figure 26A), outperforming the high anti-FR
nanoparticles (Figure 26B) and demonstrating the versatility of small molecule ligands.
Performing the magnetic relaxation studies at shorter incubation times (15 minutes)
compromised data quality for the low- folate and both anti-FR nanoparticle preparations,
leading to poor correlation coefficients (Table 5). However, the high- folate nanoparticles
achieved good correlation coefficients (R2 > 0.9) even after a 15-minute incubation,
demonstrating the enhanced detection kinetics of the high- folate nanoparticles (Figure
27). Therefore in light of these results, valency plays a critical role in the detection profile
of cancer cells using magnetic relaxation, as multivalency achieved via small molecules
(folate) facilitates fast single cell detection in blood.

Table 5: Correlation coefficients of quantification curves from time-dependent
magnetic relaxation studies.
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Figure 27: Relaxation-mediated detection of cancer cells in PBS-diluted blood after
a 15-min incubation using high-folate nanoparticles.
(Means ± SE; SE were within 1-2%, which are too small to be depicted)

Next, we studied the specificity of our high- folate MRnS towards the folate
receptor. Previously, it has been reported that antibody-carrying iron oxide nanoparticles
can specifically detect bacteria97,
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, whereas negative controls of Protein-G IONP

yielded no changes in the relaxation times107 . First, we saturated the nanoparticles’
solution with excess folate (10 mg/mL), and data indicated that the folate nanoparticles
could not detect the lung carcinoma cells (A549) under these conditions, as seen by the
concomitant absence of significant changes between the samples screened (Figure 28A).
Likewise, saturation of the culture medium with excess folate (10 mg/mL) prevented the
nanoparticles’ interaction with the cells’ folate receptors (FR), as indicated by the
absence of fluorescence emission from the plasma membrane (Figure 29A). Furthermore,
we used cells that do not express the folate receptor (H9c2), which when incubated with
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the nanosensors failed to induce any cell-concentration-dependent changes in the
solution’s T2 times (Figure 28B). Thus, these data support the hypothesis that the folate
nanoparticles interact specifically with the folate receptor at the plasma membrane of
cells expressing this receptor, facilitating magnetic relaxation detection and fluorescence
imaging.

Figure 28: Determination of the folate nanoparticles’ specificity.
A) Through either saturation of the matrix with excess folate, or B) folate-receptor (FR)
negative cells. (Means ± SE; SE were too small to be displayed (1-2%))

Figure 29: Saturation of the culture media with excess folate prevents the
association of the dye-doped folate nanoparticles with A549 cells.
The cells were incubated with the nanosensors for 2 h at 37 o C, 5% CO2 . (A) Red channel
– DiI, B) Blue channel – DAPI, C) Phase contrast).
83

After elucidating the role of nanoparticle valency in the nanoparticle –
mammalian cell interaction in the target cells’ magnetic relaxation detection trend and
sensitivities, we investigated if this behavior applied to other systems. Particularly, we
examined the role of the nanoparticle valency in the detection of bacteria. Hence for these
studies, Mycobacterium avium spp. paratuberculosis (MAP) was used, which is smaller
than mammalian alveolar cells (0.3 μm Vs 50 μm) and has dimensions comparable to
other clinically relevant pathogens. Recently, we reported the magnetic-relaxationmediated detection of MAP in complex media, observing that at low bacterial
concentrations high ΔΤ2 values were obtained, whereas at high bacterial concentrations
ΔΤ2 decreased97 . To elucidate this phenomenon, we prepared two MAP-specific MRnS
that carried different levels of anti-MAP antibodies. Specifically, two anti-MAP
nanoparticle preparations with different valency levels were prepared, by varying the
stoichiomeric ratio of anti-MAP antibody to Protein-G nanoparticles (5 μg anti-MAP:250
μL Protein-G nanoparticles Vs 0.5 ng anti-MAP:250 μL Protein- G nanoparticles. The
resulting anti-MAP MRnS had either high (4 anti-MAP molecules per nanoparticle on
average) or low (1 anti-MAP molecule per nanoparticle on average) antibody levels per
nanoparticle.
Through DLS, we observed that the anti-MAP MRnS yielded similar results to
those obtained with the nanoparticles for the FR-expressing mammalian cancer cells
(Table 6). Likewise, a valency- mediated differential behavior was also observed when we
quantified MAP in whole milk using magnetic relaxation and the anti-MAP MRnS,
following literature available protocols97 . In particular, the low-anti-MAP MRnS
exhibited high ΔΤ2 at low bacterial concentrations, whereas at high bacterial
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concentrations ΔΤ2 decreased (Figure 30A). These findings were in line with the
aforementioned studies using low valency nanoparticles and our earlier report on bacteria
detection97 . On the other hand, the high-anti-MAP MRnS demonstrated low ΔΤ2 at low
MAP concentrations, but as the target’s concentration increased ΔΤ2 increased (Figure
30B). Overall, the anti-FR and anti-MAP MRnS demonstrated similar quantifying
capabilities, despite performing these studies in different matrices (blood Vs milk).
Specifically, the high-anti-FR and high-anti-MAP nanoparticles can both quantify a
region of two orders of magnitude (104 – 106 A549 cells and 10 – 1000 MAP CFUs
respectively). Likewise, the low-anti-FR and low-anti-MAP nanoparticles can roughly
quantify an equivalent region of two orders of magnitude (104 – 106 A549 cells and ~30 –
1000 MAP CFUs), suggesting that this behavior may be attributed to the nature and
dynamics of the antibody – antigen interaction.

Table 6: Size distribution of the anti-MAP nanoparticles in the presence of various
MAP concentrations.
Means ± SE
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Figure 30: Relaxation-mediated detection of bacteria (MAP) in whole milk after a
60-minute incubation at room te mperature.
A) Low-anti-MAP (R2 = 0.97) and B) high-anti-MAP (R2 = 0.99) nanoparticles. (Means
± SE; SE was within 1-2%, which cannot be depicted)

Based on the results of the mammalian cell and bacterial MRnS, we investigated
if similar changes in the relaxation detection trends could be observed when a smaller
target was used. For this purpose, we have utilized dextran-coated and galactose-carrying
MRnS for the detection of the cholera toxin B (Ctb) subunit, as these carbohydrates are
found on the GM1 ganglioside which is cholera toxin’s cellular receptor. We anticipated
that the galactose-carrying MRnS should have exhibited a different diagnostic pattern
than the dextran-coated MRnS, as the latter nanoparticles’ coating should intrinsically
incorporate increased valency (multiple glucose moieties on the dextran-coated MRnS as
opposed to a few conjugated galactose residues on the galactose-carrying MRnS).
Experiments in water after a 5-minute incubation at room temperature revealed that the
low-valency galactose-carrying MRnS demonstrated similar behavior to the other low
valency MRnS (Figure 31A). On the other hand, the opposite trend was observed with the
dextran-coated MRnS (Figure 31B). In order to confirm the interaction between Ctb and
MRnS, we employed surface plasmon resonance analysis. Results indicated that both the
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galactose-carrying and the dextran-coated MRnS interacted with Ctb (Figures 32B and
34D). Notably, the dextran-coated MRnS provided a more prominent plasmonic signal
than the galactose-carrying MRnS, similar to what was observed via magnetic relaxation.
Taken together, these data indicate that the multivalency of the dextran-coated MRnS is a
critical contributor in the strong interaction between the MRnS and their target, and
demonstrate the potential use of MRnS for the detection of toxins in environmental
samples as part of bio-warfare and bioterrorism protection mechanisms.

Figure 31: Relaxation-mediated detection of the Cholera toxin B (Ctb) subunit.
A) Galactose-carrying MRnS (Gal-C9 -IONP) and B) dextran-coated IONP (Dex-IONP).
(Means ± SE; SE was within 1-2%).
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Figure 32: Surface Plas mon Resonance studies confirming the interaction between
MRnS and Ctb.
A) Free nonanoic-acid-terminated galactose, B) galactose-carrying MRnS (Gal-C9 IONP), C) free dextran (10kDa Dextran) and D) dextran-coated IONP (Dex-IONP).

Most importantly, these data suggest that the differential behavior of the
nanoparticles is nanoparticle-valency-dependent, as neither the size of the ligands (small
molecule Vs antibody) nor the size of the target (mammalian cell, bacterium, or toxin)
governs the interaction of the nanoparticles with a target. This is supported by the
magnetic relaxation, DLS and fluorimetry data, indicating that more high- valency
nanoparticles associate with cells at high cell density, as opposed to lower cell density. If
the nanoparticle size governed the interaction with cells, one would have expected
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comparable levels of nanoparticles associating per target regardless of cell density and no
differences between the low- and high- ligand nanoparticles detection patterns. Therefore,
in light of these studies, our previously reported findings on bacteria detection97 were
indeed attributed to the nanoparticles’ low valency. Taken together, the results of the
bacterial studies corroborate what was observed with the mammalian cells (A549) and
further support our hypothesis.
An interesting property of MRnS detection is that it is a nondestructive technique
performed in suspensions causing no damage to the cells. Therefore, we reasoned that
after MRnS identification, cells could be magnetically isolated and used for further
assays. Particularly, we hypothesized that nanoparticles with high valency would be able
to magnetically isolate a higher number of cells, due to the contribution of multivalent
interactions between the nanoparticles and their corresponding cellular targets.
Considering the folate nanosensors’ MRnS detection sensitivity and their robustness as
they do not carry any heat- labile antibodies, we studied the performance of the folate
nanoparticle preparations with low and high multivalency to magnetically isolate lung
cancer cells with an LS25 MACS® column (Miltenyi Biotec). Acknowledging the need
for circulating tumor cell isolation and propagation in order to use these cells for further
assays99 , samples of equal population A549 cells in PBS-diluted blood, which had been
screened through magnetic relaxation, were effectively isolated with either the low-folate
([Fe] = 0.75 μg/μL) or high- folate nanoparticles ([Fe] = 0.75 μg/μL) and then propagated
(Figures 33A-B). However, the nanoparticles with lower valency captured fewer cells
than the high- folate nanoparticles, as indicated by the corresponding cell counts after a 24
h propagation at 37 o C, 5% CO2 (~45,000 cells for the low- folate nanoparticles Vs
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~215,000 cells for the high- folate nanoparticles) (Figure 33C). In order to assess if the
magnetic isolation of the cells compromised their cell viability, we utilized the MTT
assay. Results indicated that the viability of the magnetically isolated cells was
comparable to that of the corresponding controls (Figure 33D), demonstrating that the
magnetic-relaxation- mediated detection and magnetic isolation of cells with the folatecarrying MRnS is non-destructive.

Figure 33: Nanoparticle-mediated magnetic isolation of FR-expressing cells.
A) Low- and B) high- folate nanoparticles. C) Hemocytomer-mediated quantification of
the captured cells after 24 h propagation at 37 o C, 5% CO2 , D) Cell viability of cells
magnetically isolated with the low- and high- folate nanoparticles (Control low – 45,000
seeded cells, Control high – 215,000 cells). (Means ± SE)
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Next, we determined the magnetic cell-capturing efficiency of the high- folate
nanoparticles, since these magnetic nanosensors exhibited enhanced detection sensitivity
through magnetic relaxation and higher magnetic isolation of cells after analysis than the
low- folate nanoparticles. Hence, after relaxation-mediated detection, the cell-containing
PBS-blood samples were incubated with various iron concentrations of high- folate
nanoparticles and then magnetically separated. Results showed that as little as 0.1 μg/μL
Fe of folate nanoparticles captured viable A549 cells, reaching a plateau after 0.75 μg/μL
Fe (Figure 34A- E). In contrast, when we used the non- functionalized nanoparticles, no
cells were isolated (Figure 34F). Overall, these data indicate that our high- folate
nanoparticle-based relaxation- mediated detection and subsequent magnetic isolation can
be used in highly sensitive non-destructive assays.

Figure 34: Folate nanoparticles facilitate the magnetic isolation of FR-expressing
tumor cells.
The captured cells were grown at 37 o C, 5% CO 2 atmosphere, and visualized 24 h after
isolation. Isolation of folate-receptor expressing cells with high- folate nanoparticles (A.
0.1, B. 0.25, C. 0.5, D. 0.75 and E. 1 μg/μL Fe). (F) Absence of cell growth when nonfunctionalized nanoparticles were used (1 μg/μL Fe).
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Lastly, we utilized iron oxide nanoparticles’ intrinsic peroxidase activity71, 72, 107
for the colorimetric high- throughput confirmation of the expression of folate receptor
(FR) on the membrane of magnetically captured and propagated A549 cells (Figure 35A).
For these studies non- fluorescent folate iron oxide nanoparticles were used. After
magnetically isolating and re-growing the A549 cells, 500 of these cells were incubated
with increasing concentrations of high- folate nanoparticles. We found that the A549 cells
in the presence of H2 O2 oxidized 3,3’,5,5’-tetramethylbenzidine (TMB) (Figure 35B) in a
nanoparticle-concentration-dependent fashion, indicating that the cells were viable and
still expressing the FR. At nanoparticle concentrations above 1.2 Fe μg/μL, the
absorbance reached a plateau. The control A549 cells, which were magnetically isolated
with folate nanoparticles but incubated with non- functionalized

nanoparticles,

demonstrated nominal peroxidase activity. This indicates that the contribution of
nanoparticles used for magnetic isolation is nominal towards the overall peroxidase
activity. In contrast, the non- folate-receptor-expressing H9c2 cells lacked any peroxidase
activity (Figure 35B), as the folate nanoparticles did not associate with these cells.
Through flow cytometry, we confirmed the expression of the FR in the magnetically
captured cells and its absence in the H9c2 control cells (Figure 36A), thus corroborating
the findings of nanoparticle- facilitated peroxidase assay (Figure 35B).
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Figure 35: Folate nanoparticles confirm the expression of FR in vitro.
A) Detection of FR-expressing cells using the folate nanoparticles’ peroxidase activity.
B) Carcinoma cells (500 A549 cells) oxidize TMB, whereas rat cardiomyocytes (H9c2)
do not. Cells were treated with non- functionalized nanoparticles (1.2 μg/μL Fe control) or
different concentrations of high- folate nanoparticles (Means ± SE).

Figure 36: Flow cytometric determination of the expression of FR.
A) H9c2 and B) A549 cells.
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Conclusion
 Small- molecule-carrying MRnS can rapidly detect a single cancer cell in blood,
without sample processing.
 Receptor- mimicking MRnS can quickly sense the presence of toxins in aqueous
media.
 MRnS can be used for the magnetic isolation of target cells for re-growth and
further analyses.
 MRnS’s intrinsic peroxidase activity can be used for the corroboration of the
presence of molecular targets in cultured cells’ plasma membrane through a
high-throughput cellular ELISA format, with the use of a single reagent
(MRnS) and hydrogen peroxide.
 The magnetic-relaxation- mediated detection pattern is governed by the MRnS’s
valency, but neither by the target’s size, the sample’s matrix nor the nature of
the ligand.

Discussion
Nature widely employs highly selective multivalent interactions87-96 . From
enzymes and their substrates, to receptor – ligand pairs and antibody – antigen
complexes, these associations are highly specific, despite being weaker than covalent
interactions. For instance, the multivalent interaction between hemaglutinin of influenza
virions and sialic acid moieties on bronchial epithelium cells mediates viral infection92 .
Specifically, recent studies indicate that multivalency, apart from participating in the
initial attachment of a pathogen (i.e. virus, toxin) to a target cell, is critical for uptake via
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complex, highly regulated endocytic processes, in addition to direct fusion109 . In line with
these observations, recently, a multivalent gold nanoparticle conjugate has been reported
to transform a weakly binding and biologically inactive small molecule into a potent
multivalent nanoagent that effectively inhibits HIV-1 fusion to human T cells110 .
Considering the importance of multivalency on molecular recognition events, it is
critical to assess its role in the sensitivity and detection pattern of novel nanoparticlebased diagnostic methods. Hence, in this chapter we addressed the fundamental question
of how the nanoparticle valency affects the interaction of MRnS with cells and what are
the consequences in the magnetic-relaxation- mediated detection and magnetic isolation
of these target entities. Our results indicate that nanoparticles with low valency switch
from an assembled to a quasi-dispersed state as the target concentration increases, and
this shift is accompanied with decrease in the ΔΤ2. On the other hand, nanoparticles with
high valency move from a sparsely assembled to an extensive binding/clustered state,
with a concomitant increase in ΔΤ2 that is observed during this transition. Interestingly,
similar results were obtained when mammalian and bacterial cells were used, suggesting
that the previously reported unique trend in the detection of bacterial cells was attributed
to the different levels of antibodies conjugated to the nanoparticles97,
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. The

aforementioned shift in the ΔT2 trend was also consistent when toxin-detecting MRnS
were used, further supporting that it is the nanoparticle valency that modulates this
behavior and not the target’s size. Additionally, the shift in the relaxation detection
pattern is valency-regulated, as neither the matrix (blood, milk or water), the ligand size
(folate, galactose or anti-FR), nor the nanoparticle’s coating (polyacrylic acid Vs dextran)
affected the quantification trend. Hence, valency engineering should be a critical aspect
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in the synthesis of sensitive MRnS and perhaps other nanoparticle-based diagnostic
assays.
Another important element in the design of robust and affordable nanosensors is
the utilization of non- labile and readily available probes. In our studies, nanoparticles
with high small molecule valency (high- folate nanoparticles) facilitated single cell
detection and quantification in whole erythrocyte-containing blood, outperforming their
low valency counterparts (low-folate nanoparticles) and antibody-carrying nanosensors
(low- or high-anti-FR nanoparticles). Therefore, as it was recently demonstrated that even
a single metastatic cancer progenitor cell can successfully induce tumor formation108 ,
high- folate carrying nanoparticles may be used for the early detection of tumor cells in
blood that overexpress the folate receptor. Furthermore, as the iron oxide nanoparticles
can be easily conjugated via “click chemistry”, other small molecules may be used for the
synthesis of high- valency nanosensors, capable of detecting rare circulating tumor cell in
blood that may express other biomarkers. Small molecules, apart from being cheaper and
more robust than antibodies, can offer comparable specificity and can be easily utilized
for the engineering of the nanoparticle valency, due to their minimal steric hindrance.
Since small- molecule-carrying nanoparticles can sense single cells, as opposed to
antibody-carrying nanoparticles, the wider utilization of small molecules in molecular
diagnostics is expected. For instance, bacteria can be targeted with small molecules
screened from combinatorial libraries, leading to the development of bacterium-specific
small- molecule-carrying nanoparticles, which can achieve reliable and sensitive detection
at the points-of-care and in the developing world58 .
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CHAPTER V: ASSESSMENT OF BACTERIAL METABOLISM AND
DRUG RESISTANCE VIA MRnS

Introduction
In the last 20 years, there has been a dramatic increase in the emergence of
antibiotic-resistant bacteria, leading to elevated bacterial pathogenesis at the global level
111, 112

. In particular, the emergence of drug resistant strains of Mycobacterium

tuberculosis

(XDR-TB) and

the

increased

occurrence of methicillin-resistant

Staphylococcus aureus (MRSA) infections, indicate that drug resistance is a major public
health issue111, 112 . Recent reports indicate that in the United States MRSA infections
cause more deaths than HIV/AIDS, whereas the development of new antibiotics has
significantly slowed down since the early 1990s111-113 . Therefore, developing sensitive
and cost-efficient detection systems that can quickly identify if (i) a particular bacterium
is resistant to antibiotics, (ii) the pharmacological agents which the microorganism is
susceptible to and (iii) the agents’ appropriate effective dosage is vital for successful
treatment and prevention of epidemics. Traditionally, the determination of antimicrobial
susceptibility to antibiotics is facilitated after isolation of the microorganism and
examination of its growth in media containing various antimicrobial agents, in a process
that can take up to 48 hours114, 115 . Hence, developing fast and accurate antimicrobial
susceptibility assays is important for the clinic and the pharmaceutical industry.
Nanotechnology offers a unique alternative for the development of detection
methods for bacterial targets that require less preparation time and smaller sample
volumes, while offering enhanced sensitivity and faster detection kinetics24, 33, 75, 76, 97 . In
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particular, nanosensors that not only directly detect the presence of a specific pathogenic
agent, but can also make an indirect detection through the assessment of the pathogen’s
metabolic activity, e.g., via the monitoring of the rate of consumption of nutrients in
solution, would be of great utility. The development of such nanosensors will be of
significant importance, because they will be able to interrogate whether the pathogen is
still metabolically active and reproducing in the presence of a particular antibiotic.
Currently, most contemporary nanoparticle-based immunoassays cannot distinguish
between metabolically active, senescent and dead pathogens97, 116 .
Considering these, we first utilized a novel gold nanoparticle-based method for
the assessment of bacterial susceptibility via surface plasmon resonance shifts in
transparent media. However, as microorganisms, like Staphylococcus epidermidis and
Neisseria spp. among many others, can be present in the blood of infected patients
(septicemia), requiring isolation and growth in blood-containing media, we designed
MRnS for the assessment of antimicrobial susceptibility in blood117, 118 . We reasoned that
MRnS could be a more robust system, quickly determining bacterial susceptibility
independent of the solution’s optical properties via water relaxation50, 52 . According to the
literature, it is widely acknowledged that a major benefit of using magnetic relaxation
methods is that molecular detection can be achieved in opaque media, such as cell
lysates, tissue extracts and complex biological fluids, notably blood, with high specificity
and sensitivity50, 52, 97 . Therefore, we hypothesized that bacterial-susceptibility- monitoring
MRnS could be designed to differentially respond to the presence of various
concentrations of nutrients, such as complex carbohydrates (e.g. starch). Although
superparamagnetic nanoparticles have been used as magnetic relaxation sensors for the
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detection of various targets50-53, 70, 97, 119-122 , these nanoprobes have not been previously
utilized for the detection of metabolic activity, which might lead to the potential
development of nanosensors capable of determining antimicrobial susceptibility in
complex media.

Materials and Methods
Synthesis of Dextran-coated Gold Nanoparticles.
To 100 ml of a 1% aqueous solution of Dextran T – 10 (10 kDa, GE/Pharmacosmos), 1
ml of 10-2 M HAuCl4 (Sigma) was added and stirred while heating. The solution was
allowed to boil until its color turned pink, indicating the formation of gold nanoparticles
in solution.123 . The reaction mixture was boiled for 30 more minutes. Then, the solution
was cooled down to room temperature and washed three times with distilled water using
an Amicon 8200 cell (Millipore ultrafiltration membrane YM – 30 kDa).

Characterization.
Transmission electron microscopy (TEM) was done using a FEI Tecnai F30 instrument
on dextran-coated Au-NP (Dex-Au-NP) samples spotted on a carbon-coated copper grid.
Dynamic light scattering (DLS) studies were done using a PDDLS CoolBatch 40T
instrument using Precision Deconvolve 32 software. FT-IR experiments were done in a
Perkin Elmer Spectrum 100 FTIR spectrometer using samples spotted on plastic cover
slips.

UV-vis studies with Dex-Au-NP and E. coli.
E. coli (strain 8739 from ATCC, 106 CFU) was grown in MH broth (DIFCOT M, BD), for
2 hours at 37o C in the presence or absence of ampicillin. Each nanoparticle solution (400
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μl Dex-Au NP in 600 μl distilled water) was spiked with 10 μl of specimen and examined
on a Cary 300 UV-Visible spectrophotometer (Varian Inc.). Addition of Con A (Sigma,
10 μgml-1 ) resulted in changes in the absorption profiles of the Dex-Au-NP, which were
monitored with the Cary 300 UV-Vis spectrophotometer, at various time intervals.

High-throughput determination of antimicrobial susceptibility using Dex-Au-NP.
In each well of the 96-well plate (Corning) 100 μl of Dex-Au-NP (40:60 v:v) were added.
Then 1 μl aliquots of each samples with either sterile MH medium, E. coli grown in 64
μg ampicillin, 2 μg ampicillin, 0 μg ampicillin, or heat-inactivated E. coli were added in
triplicates in various wells of the plate. All bacterial cultures were grown as stated above,
whereas heat inactivation of E. coli was achieved by autoclaving the culture immediately
after the bacteria (106 CFU) were added into the MH broth, preventing any bacterial
metabolism and proliferation. The absorbance of each well was monitored on a Synergy
HT microplate reader (BioTek) prior and after Con A addition (10 μg/ml final
concentration). As all wells had the same surface plasmon peak prior the addition of Con
A, the wavelength difference (Δλ) was denoted as the wavelength with maximum
absorbance of the sterile control minus the wavelength with maximum absorbance of the
specimen, both under Con A- induced clustering. Control samples of sterile medium or
heat-inactivated bacteria had a Δλ equal to zero and were depicted as purple in our color
map. Samples that exhibited Δλ values below 4 nm indicated the absence of bacterial
growth, suggesting the presence of an effective inhibitory antibiotic concentration, and
were depicted as green. Finally, samples with Δλ values above 4 nm indicated that
bacterial growth occurred, due to either absence of antibiotic or low antibiotic
concentration, and were denoted as red.
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Reagents for the synthesis of MRnS.
All the reagents used were of AR (Analytical Reagent) grade. Nitrogen-purged doubledistilled water was used throughout the reaction. Iron salts, FeCl2 .4H2 O and FeCl3 .6H2 O,
were obtained from Fluka. Dextran (MW 10kDa) was received from Amersham. TEOS:
tetraethylorthosilicate (Fluka), APTS: 3-(amino-propyl)triethoxysilane (Aldrich) and
THPMP: 3-(trihydroxysilyl)propylmethyl-phosphonate (Gelest Inc) were used as
received from the suppliers.

Synthesis of MRnS.
The dextran-coated iron oxide nanoparticles were prepared as previously reported in the
literature52 . The aminated silica-coated iron oxide nanoparticles were prepared using a
previously published protocol124 , with modifications in order to yield stable nanoparticles
via a water-based synthesis. Specifically, iron oxide nanocrystals were formed via the
alkaline precipitation method, by mixing a solution of iron salts (0.202 g FeCl2 .4H2 O,
0.488 g FeCl3 .6H2 O, 88.7 μL HCl in 2 mL distilled water) with an ammonium hydroxide
solution (830 μl NH4 OH in 15 mL distilled water). Then, 20 seconds after the initiation
of the iron oxide nanocrystal formation, a TEOS-THPMP-APTS solution was added
(6180 μL THPMP, 2680 μL TEOS, 670 μL APTS) under continuous vortexing. The assynthesized nanoparticle suspensions were centrifuged to remove large particles. Both the
amino-silica- and dextran-coated nanoparticles were washed several times with distilled
water and concentrated through an Amicon 8200 cell (Millipore Ultrafiltration membrane
YM – 30 kDa). Finally, the nanoparticle suspensions were stored at 4 o C until further use.
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Conjugation of Concanavalin A to silica-coated iron oxide nanoparticles.
Two milliliters of aminated silica-coated iron oxide nanoparticles (R2=225 mM-1 s-1 , [Fe]
= 0.47 mg/ml) were used for the conjugation of Con A to the nanoparticles’ surface.
Initially, in 1 mL of cold MES buffer (0.1M, pH 6.0) 4.8 mg EDC (Pierce) and 3 mg
NHS (Pierce) were dissolved. Then, 2 mg of lyophilized Con A (Sigma) were dissolved
in 2 mL cold MES buffer (0.1M, pH 6.0). Subsequently, the Con A solution was mixed
with the EDC/NHS solution, followed by a 3- minute low-speed rotary mixing at room
temperature. Finally, the aminated silica-coated iron oxide nanoparticles were added to
the Con A (amine-reactive NHS-ester form) solution, followed by periodical rotary
mixing at low speed and storage at 4 o C. The resulting Con A-conjugated silica-coated
iron oxide nanoparticles were purified from any unbound protein via magnetic separation
using an MES buffer-equilibrated (0.1M) LS25 MACS® column (Miltenyi Biotec).

MRnS characterization.
Dynamic light scattering (DLS) studies were done using a PDDLS CoolBatch 40T
instrument using Precision Deconvolve 32 software. Iron concentration was determined
spectrophotometrically after acid digestion of the nanoparticles’ suspension, whereas R2
relaxivity measurements were obtained using a 0.47T mq20 NMR analyzer (Minispec,
Bruker, Germany). Starch sensing with the magnetic nanoparticles was performed using
serial dilutions of starch (~75% amylopectin, ~25% amylose, S-516, Fisher) in non-starch
containing MH broth (DIFCO TM, BD). The concentration of Con A conjugated to the
silica-coated iron oxide nanoparticles was determined through the BCA assay, in
accordance to the manufacturer’s protocol (Pierce), after magnetic separation of the
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nanoparticle suspension using an MES buffer-equilibrated (0.1M) LS25 MACS® column
(Miltenyi Biotec).

Bacterial cultures.
In order to investigate if the dextran-coated iron oxide nanoparticles can monitor the
starch utilization due to bacterial metabolic activity, different populations of Escherichia
coli (strain 8739 from ATCC) were grown in starch-containing MH broth (DIFCO TM,
BD) for 2 hours at 37 o C. For determination of the minimum inhibitory concentration,
Escherichia coli (106 CFU), Serratia marcescens (ATCC, 106 CFU) and Shigella sonnie
(strain 9290 from ATCC, 106 CFU) were grown in a starch-containing MH broth
(DIFCO TM, BD), for 2 hours at 37o C in the presence or absence of ampicillin. For
determination of MIC in blood, bacterial stocks (106 CFU) were grown in the presence or
absence of ampicillin in a 5%-blood-supplemented starch-containing MH broth, for 2
hours at 37 o C. Defibrinated sheep blood was obtained from the Colorado Serum
Company, simulating bacterial isolation and growth in typical blood agar plates. For
studies requiring heat inactivation, E. coli bacteria were autoclaved in the culture tubes
for 10 minutes. Upon incubation or inactivation, all bacterial stocks were placed in a
Fisher Isotemp freezer (Fisher Scientific, Hampton, NH), until further use.
Sample preparation for relaxation measurements.
Aliquots of 10 μl (either of the aforementioned bacteria or media) were added into 190 μl
nanoparticle working solution (0.02 μg/μL in Ca2+/Mg2+-free 1X PBS for both the
dextran-coated and Con A-conjugated polysaccharide nanosensors). For the dextrancoated polysaccharide nanosensors, 10 μL Con A (Sigma, 1 μg/μl) were added in order to
induce nanoparticle clustering.
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Measure ment of proton relaxation times.
Spin-spin relaxation times (T2) were measured using a 0.47 T mq20 NMR analyzer
(Minispec, Bruker). T2 values were obtained before and after addition of the aliquot, and
through the time course of the study. For the quantification of starch, we prepared serial
dilutions of sterile starch-supplemented MH broth (DIFCO TM, BD) in sterile non-starchsupplemented

MH

broth (DIFCO TM,

BD).

Subsequently,

the

dextran-coated

polysaccharide nanosensors’ sensitivity and dose response to the analyte (starch) was
evaluated, by monitoring the changes in the spin-spin relaxation time. In this case, ΔΤ2 is
denoted as the difference between the relaxation time of the solution’s initial dispersed
state before addition of the MH broth aliquot (T2in ) and the solution’s T2 after addition of
the MH broth aliquot (T2’). Thus, ΔT2 = |T2’-T2initial|. For all other measurements,
including E.coli’s metabolic activity monitoring via carbohydrate quantification and
magnetic relaxation- mediated antimicrobial susceptibility assessment, ΔΤ2 is denoted as
the difference between the T2 of a sample and the corresponding sterile control sample
(ΔΤ2 = |Τ2sample – T2control|), where the sterile control was starch-containing MH which is
used for the growth of these microorganisms. The sterile control used for the
nanoparticle- mediated antimicrobial susceptibility assessment in blood was 5%-bloodsupplememted starch-containing MH broth. All experiments and measurements were
carried out in triplicate and data were expressed as mean ± standard error, unless
otherwise denoted. Response curves were obtained by fitting the data on a sigmoidal
curve, using Origin 7.5 (OriginLab, Northampton, MA). Statistical analyses were
performed on SPSS 11.5 (SPSS Inc., Chicago, IL).
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Broth dilution assay for determination of Minimum Inhibitory Concentration
(MIC).
Broth dilution assay (standard method for measuring MIC) was achieved by inoculating
serial dilutions of ampicillin in sterile starch-containing MH broth, with either E. coli, S.
marcescens, or S. sonnei (106 CFU), followed by a 24- hour long incubation at 37o C.
Bacterial growth was assessed based on the broth’s turbidity, where absence of turbidity
was an indicator of successful antimicrobial susceptibility. The lowest ampicillin
concentration where the MH broth is clear indicates the minimum concentration of
ampicillin that can successfully inhibit bacterial growth114, 115 .

Results
Initially we developed a spectrophotometric antimicrobial susceptibility assay,
based on the concanavalin- induced self-assembly of dextran-coated gold nanoparticles
(Dex-Au-NP) in response to bacteria’s metabolic state. Dex-Au-NP have been previously
used as nanosensors for the detection of glucose125 , due to the nanoparticles’ ability to
cluster in the presence of Concanavalin A (Con A), a protein with high affinity towards
carbohydrates125, 126 . We reasoned that in the (i) absence of an inhibitory compound, (ii)
presence of an ineffective antibiotic, or (iii) at non- inhibitory antibiotic concentrations,
the bacteria will proliferate, reducing the levels of nutrients, such as carbohydrates in
solution. Under these conditions, Con A would facilitate the assembly of the Dex-Au-NP
to carbohydrates on the surface of the growing bacterial population, creating a semidispersed state and favoring formation of small clusters (Figure 37A). Meanwhile, in the
case of an effective antibiotic, there would be suppression of the bacterial metabolism
with corresponding reduction in the uptake of carbohydrates by the bacteria. Thus, the
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excess complex carbohydrates in solution presumably would promote the concanavalininduced clustering of Dex-Au-NP. This would result in the formation of larger Aunanoassemblies, leading to a significant red-shift of the surface plasmon band (Figure
37B), that is proximal to the surface plasmon band of a sterile solution containing Con Aassembled Dex-Au-NP (Figure 37C).
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Figure 37: Proposed model for Dex-Au-NP-me diated antimicrobial susceptibility
assessment.
In the absence of bacterial carbohydrate uptake (B) or in sterile conditions (C), addition
of Con A results in the formation of large nanoassemblies and large shifts in the surface
plasmon band, due to the presence of free carbohydrates in solution. During bacterial
growth (A), the increased population of bacteria utilizes more carbohydrates, resulting in
a decrease in the amount of free carbohydrates and a corresponding decrease in the size
of the gold nanoclusters, causing lower shifts in the plasmonic band.

For the spectrophotometric assessment of antimicrobial susceptibility, we used
dextran-coated gold nanoparticles. Dynamic light scattering results (Figure 38A) showed
that the Dex-Au-NP preparation was composed of monodispersed nanoparticles of 25 ± 5
nm in size, as confirmed by TEM, which showed spheres with diameter in the range of 22
± 3 nm (Figure 38A, inset). The Dex-Au-NP were highly stable in water for up to a year
of storage at 4o C, and were easily suspended in a solution containing sterile MH bacterial
medium with no precipitation. In our synthetic procedure, dextran served the dual role of
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a reducing and a stabilizing agent. Dextran reduces AuIII to Au0 and substitutes the role of
citrate in previously reported preparations127, 128 . Indeed, FTIR data showed that some of
dextran’s hydroxyl groups got oxidized to aldehyde groups, a process that is coupled to
the reduction of AuIII to Au0 (Figure 38B). Finally, the evolved gold nanoparticles were
stabilized by the dextran in solution, again substituting citrate’s role. The presence of
dextran peaks in Dex-Au-NP demonstrated that dextran was an integral part of the assynthesized nanoparticles, providing stability to them.

Figure 38: Characterization of the Dex-Au-NP.
A) Particle size distribution with corresponding TEM image (inset). B) FT-IR spectra of
free dextran and Dex-Au-NP. The peak at 1698 cm-1 represents the formation of aldehyde
groups on Dex-Au-NP.

UV-vis analysis of the Dex-Au-NP in either PBS or sterile MH medium revealed
the characteristic profile for gold nanoparticles (Figure 39A) with an absorption
maximum at 531 ± 0.1 nm, which was unaffected when the nanoparticles were in the
presence of increasing amounts of antibiotic, E. coli bacteria or a combination of both
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(Table 7, Figure 39B). No clustering or precipitation was observed for weeks, which
supports the idea that the nanoparticles are stable in media containing nutrients (complex
carbohydrates) and bacteria. However, when Con A (10 μg/ml) was added to the
nanoparticles, a significant red-shift was observed, with a maximum surface plasmon
peak at 566 ± 0.3 nm (Table7) due to cluster formation, as confirmed by DLS. Notably,
the presence of the antibiotic in sterile MH medium, which was free from any bacteria,
did not affect the nanoparticles’ absorption profile under Con A-induced clustering
conditions (Figure 40).

Figure 39: UV-vis spectroscopic characterization of Dex-Au-NP in culture media.
A) UV-Visible spectra of Dex-Au-NP in the absence of Con A (non-assembled
conditions). B) In the absence of Con A, the Dex-Au-NPs were in a non-assembled state,
exhibiting the same spectral characteristics, regardless of the presence of bacteria and
antibiotic. The samples with ampicillin (64, 8, and 2 μg) and the bacterial growth control
(0 μg ampicillin) contained aliquots from liquid cultures initially inoculated with 106
CFU E. coli.
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Table 7: Absorption maxima of Dex-Au-NP in various media with or without E. coli
in the presence of ampicillin (Amp).
Means ± SE. [a] Represents the difference between the absorption maxima of the control
sample (MH Broth + Con A) and the test sample.

Dex-Au-NP in various media

λmax (nm)

PBS
MH Broth
MH Broth + 64 μg Amp + E. coli (106 )
MH Broth + Con A
MH Broth + Con A + E. coli (106 ) + 64 μg Amp
(inhibitory)
MH Broth + Con A + E. coli (106 ) + 2 μg Amp (non
inhibitory)

531 ± 0.1
531 ± 0.1
531 ± 0.1
566 ± 0.3

Δλ[a]
(nm)
-

564 ± 0.4

2

557 ± 0.6

9

Figure 40: Dex-Au-NP’s spectral characteristics in sterile MH broth under Con Ainduced clustering.

110

Next, we examined whether bacterial metabolic activity can be assessed via the
Dex-Au-NP’s surface plasmon band changes. In these studies, E. coli (106 CFU) were
incubated for 2 hours at 37 o C in MH broth, in the presence of various concentrations of
ampicillin. Then, 10 μl aliquots of these samples were added into the Dex-Au-NP
solution. As described before, despite the presence of bacteria and antibiotic, the samples
exhibited identical absorption spectra, under non-assembled conditions (Figure 39B).
However, after addition of Con A (10 μg/ml) and a 30- minute incubation at 25 o C,
significant changes were observed (Figure 41). The surface plasmon band of a sample
containing a low, non- inhibitory, concentration of ampicillin (2 μg) was 557 ± 0.6 nm,
corresponding to a difference (Δλ) of 9 nm between the control and the sample (Table 7,
Figure 41A). Similar differences were also observed in samples containing bacteria
actively proliferating in the absence of the antibiotic. The observed 9 ± 0.6 nm difference
is the result of Dex-Au-NP re-dispersion due to an increase in the bacterial population
and subsequent decrease of available free carbohydrates. However, when a higher and
inhibitory amount of ampicillin (64 μg) was used, the surface plasmon of the
nanoparticles was 564 ± 0.4 nm, corresponding to a difference of only 2 nm (Table 7,
Figure 41B). Under these conditions, the surface plasmon band was closer to that of the
sterile control, due to the higher amount of free carbohydrates that have not been utilized
by the bacteria as their metabolism was suppressed, hence promoting extensive
concanavalin- induced Dex-Au-NP clustering. The presence of large gold nanoclusters in
the sample with inhibitory antibiotic concentration was confirmed by DLS studies.
Specifically, at 64 μg ampicillin, 60% of the Con A- induced clusters were 350 nm or
larger in diameter, whereas the remaining 40% had diameters below 100 nm. In contrast,
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at the low non- inhibitory antibiotic concentration (2 μg), only 40% of the Con A- induced
clusters were 350 nm or larger, while 60% had diameters of 100 nm or smaller. These
results confirm that under conditions of bacterial growth the gold nanoclusters were
smaller than those formed under inhibition or absence of bacterial growth and
substantiate the observed changes in surface plasmon.

Figure 41: Distinct plas monic s hifts of Dex-Au-NP under Con A-induced clustering
conditions in bacterial cultures supplemented with antibiotics.
A) Bacterial growth in the presence of the non- inhibitory ampicillin concentration of 2
μg. B) Absence of bacterial growth corresponding to the inhibitory 64 μg ampicillin
concentration.

We then asked if one could use the developed Dex-Au-NP in antimicrobial
susceptibility assays. The goal of an antimicrobial susceptibility test is to predict the in
vivo success or failure of a particular antibiotic therapy by measuring the growth response
of an isolated organism in the presence of a particular antimicrobial agent114 . Results are
expressed in terms of the antibiotic’s minimum inhibitory concentration (MIC), which is
defined as the antibiotic’s minimum concentration that can inhibit the growth of an
112

isolated microorganism. Accurate determination of the MIC is critical for the
identification of an effective compound and its’ administration at dosages that prevent
adverse side effects, such as renal toxicity. Considering that current MIC determination
methods, such as broth dilution or disk diffusion assays, yield results in approximately 24
hours115 , we examined if our Dex-Au NP-based method can yield similar results but
faster and without sacrificing reliability. For these studies, E. coli (106 CFU) were
incubated for only 2 hours at 37

o

C in MH broth, in the presence of different

concentrations of ampicillin. Then, aliquots of these samples were incubated with DexAu-NP for 30 minutes at 25 o C, in the presence of Con A (10 μg/ml). The ampicillin MIC
for this E. coli strain was found to be 8 μg, because at this concentration the surface
plasmon band shift of the nanoparticles was statistically different from that of the sample
containing bacteria growing in the absence of antibiotic (Figure 42A). Confirmation of
our results was achieved via a broth dilution assay115 . Bacterial growth was assessed
based on the broth’s turbidity, where absence of turbidity was an indicator of successful
antimicrobial susceptibility. The lowest ampicillin concentration as determined by this
method was also 8 μg (Figure 42A). This concentration was identical to the Dex-AuNP/Con A-determined MIC, though the nanoparticle-based method yielded the same
results within 3 hours as opposed to 24 hours.
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Figure 42: Spectrophotometric determination of antimicrobial s usceptibility using
Dex-Au-NP.
A) Determination of the minimum inhibitory concentration using the surface plasmon
peak shift of Dex-Au-NP and confirmation via the turbidity method (numbers indicate the
amount of ampicillin) (Means ± SE). B) Determination of minimum inhibitory
concentration in high-throughput format using Dex-Au-NP and Con A. Purple squares
indicate absence of bacterial metabolism (Δλ = 0 ± 0.4 nm), green areas demonstrate
inhibition of bacterial metabolism (Δλ = 2 ± 0.4 nm), and red wells show active bacterial
metabolism (Δλ = 9 ± 0.6 nm). Group: (a) Sterile MH broth, (b) E. coli (106 CFU) grown
in the absence of ampicillin, (c) heat- inactivated E. coli (106 CFU) in MH broth, (d) and
(e) E. coli (106 CFU) grown in the presence of 64 and 2 μg ampicillin, respectively.
Following wells include replications of these groups, obeying the above pattern. Group
(f) consists of additional control samples, similar to (a).Absence of bacterial growth
corresponding to the inhibitory 64 μg ampicillin concentration.

In subsequent studies, we investigated the potential use of Dex-Au-NP for the
determination of antimicrobial susceptibility in high-throughput format. In these studies,
samples of heat- inactivated E. coli (106 CFU) and E. coli (106 CFU) grown in the
presence or absence of ampicillin were screened with the Dex-Au-NP on a 96-well plate
using a microtiter plate reader. Addition of Con A, followed by a 30- min incubation at 25
o

C, resulted in distinct changes of the surface plasmon band, similar to those described

above with standard errors of less than 0.6 nm. This allowed the categorization of the
samples in inhibitory (64 μg ampicillin; Δλ < 4 nm) or non- inhibitory (2 and 0 μg
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ampicillin; Δλ > 4 nm) cohorts, denoted as green and red areas respectively (Figure 42B).
Also, the wells with heat- inactivated bacteria had the same absorption maximum with the
sterile medium (Δλ = 0 nm), collectively classifying these samples as control and
denoting them as purple. In control studies, high-throughput spectrophotometric
screening of 100 μl aliquots of bacterial cultures (106 CFU) incubated for 2 hours in the
presence of ampicillin did not reveal significant changes in the culture’s absorbance at
500 nm (Figure 43), indicating that the Dex-Au-NP can facilitate reliable and fast MIC
detection. Overall, these demonstrated the reproducibility and capability of dextrancoated gold nanoparticles to rapidly screen multiple samples simultaneously in a highthroughput format, outperforming the traditional 24-hour- long.turbidity method.

Figure 43: Unassisted determination of MIC by monitoring the absorbance at 500
nm.
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Although Dex-Au-NP are ideal for transparent samples, their use in opaque media
is limited. Thus, to circumvent this limitation, we developed MRnS-based antimicrobial
assays. Initially, we reasoned that the polysaccharide nanosensors’ clustering should
result in a significant change in the spin-spin relaxation time (T2) of the solution’s water
protons, facilitating the reliable identification of effective antimicrobial agents. This can
be achieved using dextran-coated MRnS along with a protein with high affinity to
carbohydrates, such as Concanavalin A (ConA), in a competition assay. Specifically, we
hypothesized that upon Con A- induced clustering, the dextran-coated MRnS could
differentially respond to the polysaccharide levels associated with bacterial metabolism
and growth. Hence, the higher the rate of bacterial metabolic activity, the fewer amount
of the available polysaccharides (such as starch) would be, resulting in prominent
changes in the sample’s ΔΤ2 when compared to those of the sterile medium (Figure 44).
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Figure 44: Proposed model for the assessment of antimicrobial susceptibility using
dextran-coated polysaccharide MRnS and Concanavalin A.
In this competition assay, the dextran found on the surface of the iron oxide nanoparticles
and the starch in solution compete for binding to Con A’s carbohydrate-binding domains.
This results in changed in the degree of Con A- induced nanoparticle clustering upon
bacterial metabolic uptake of the starch.

In our first set of experiments with MRnS, we investigated if dextran-coated iron
oxide nanoparticles (Figure 45A, R2 = 300 mM-1 s-1 ) were responsive to changes in starch
concentration upon bacterial growth. Initial studies in phosphate buffered saline showed
that the nanosensors quickly clustered after addition of Con A, (Figure 45B) forming
stable nanoassemblies that induced prominent changes in the T2 within an hour (Figure
46A). During initial optimization studies, we found that a Con A concentration of 1
μg/μL and a nanoparticle solution with a concentration of 0.02 μ g Fe/μL provided
optimum results (Figure 46B). Thus, we used this iron concentration in all of our
experiments. Lower iron concentrations increased the error in the measurement, whereas
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higher concentrations sacrificed sensitivity and detection kinetics, requiring higher
concentrations of Con A.

Figure 45: Size distribution of dextran-coated polysaccharide MRnS.
A) Before addition of Con A, and B) one hour after Con A addition (1 μg/μL), indicating
the formation of nanoparticle clusters.

Figure 46: Con A-induced changes in T2.
A) Treatment with Con A (1μg/μL) facilitates prominent changes in the solution’s spinspin relaxation time (T2). B) Standard curve for determination of Con A’s optimum
concentration using a nanoparticle solution with a concentration of 0.02 μg Fe/μl. (Means
± SE)
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Next, we assessed the capability of our nanosensors to sense variations in MH
broth’s starch concentration. In these experiments we added our nanosensors (0.02 μg
Fe/μL) to solutions containing increasing amounts of starch in MH broth and Con-A (1
μg/μL). We anticipated that in this competition assay and at low concentrations of starch,
the Con A would be able to cluster the dextran- coated magnetic nanosensors resulting in
prominent changes in T2. However, as the amount of starch increases, smaller changes in
T2 are expected, as Con A would primarily bind to starch. Results showed that after a 30minute- long incubation at room temperature, a dose-dependent response curve was
obtained (R2 = 0.99), demonstrating that the changes in T2 were inversely proportional to
the starch concentration (Figure 47A), in accordance with our hypothesis. Notably, the
dextran-coated polysaccharide nanosensors were able to quantify starch from
concentrations of 77.5 ng/μL, which is the initial starch concentration of a typical MH
broth, to 1.5 ng/μL.

Figure 47: MRnS-mediated sensing of polysaccharide levels and monitoring of
bacte rial metabolic activity.
A) Quantification of starch in sterile MH broth, and B) determination of starch
consumption due to bacterial metabolism in MH broth, using the dextran-coated MRnS.
(Means ± SE)
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We then examined if these polysaccharide MRnS can respond to changes in the
starch concentration of MH broth (initial starch concentration = 77.5 ng/μL) due to
bacterial metabolic activity. In these experiments, magnetic nanoprobe solutions (0.02 μg
Fe/μL) containing aliquots of increasing amounts of E. coli were incubated with Con A.
Results showed that upon addition of Con A, a dose-dependent response was observed
(R2 = 0.99), after a 30- minute incubation at room temperature (Figure 47B). The higher
the bacterial population (expressed in Colony Forming Units, CFU) the larger the
changes in T2 (ΔΤ2). This is attributed to the fact that higher bacterial populations utilize
more amounts of starch via their metabolic activities, resulting in a concomitant reduction
of the media’s carbohydrates. As a result, addition of Con A promotes the formation of
extensive nanoassemblies, as expected. Notably, even at low bacterial populations (102 –
104 CFUs) significant changes in T2 were detected. Hence, this demonstrates the high
sensitivity of the nanosensors in detecting bacterial metabolic activity, even in the
presence of as few as 102 CFUs. This is of grave importance in order to prevent
septicemia, as very few bacteria in circulation may cause systemic infection leading to
death.
In control experiments we found that in the absence of Con A, the presence of
increasing amount of bacteria does not affect the T2 of the nanoparticle solution.
Specifically, all samples containing either sterile media or different bacterial loads
exhibited similar T2 values, suggesting that the presence of bacteria does not alter the
spin-spin relaxation times of the non-assembled state (Figure 48). To further corroborate
our results, we used heat- inactivated bacteria to halt their metabolic activities.
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Consequently, nominal differences were observed between the samples of heatinactivated bacteria and sterile medium (Figure 49).

Figure 48: In the absence of ConA, MRnS exhibit the same T2 regardless of the
presence of bacteria.
Results obtained after a 30- minute incubation. 1. Water, 2. Sterile medium (with starch),
3. Sterile medium (no starch), 4. 102 CFU E. coli, 5. 103 CFU E. coli, 6. 104 CFU E. coli,
7. 105 CFU E. coli, 8. 106 CFU E. coli, 9. 108 CFU E. coli, 10. 109 CFU E. coli. (Means ±
SE)

Figure 49: The behavior of MRnS is independent of the heat-inactivated bacterial
population, but it is dependent of active bacterial metabolis m.
The graph depicts data obtained after a 30-minute incubation at room temperature, in the
presence of Con A. Linear fit was applied with an R2 = 0.14 (OriginPro 7.5). (Means ±
SE)
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Based on our dextran-coated MRnS’s ability to sense carbohydrate utilization due
to microbial metabolism, we examined if these nanosensors can be used for the
identification of antimicrobial susceptibility and determination of an antibiotic’s
minimum inhibitory concentration (MIC). As MIC predicts the success of a particular
antibiotic and is an important clinical parameter that dictates treatment in order to
minimize adverse side effects, such as renal failure, quick determination of MIC is of
paramount importance114 . Thus, we first examined if the presence of antibiotics in the
media might induce non-specific nanoparticle clustering, potentially interfering with the
assay’s carbohydrate specificity. In these control studies, a bacterial population (106
CFU) which is typically used in MIC experiments was incubated in the presence of
different antibiotic concentrations. Results showed that these culture conditions did not
affect the spin-spin relaxation times of the nanoparticle solution, indicating absence of
non-specific antibiotic-mediated nanoparticle assembly (Figure 50).
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Figure 50: MRnS are not affected by the presence of bacteria and antibiotic.
In the absence of ConA, the IO NPs exhibited the same T2, regardless of the presence of
bacteria and antibiotic. 1. Water, 2. Sterile medium (with starch), 3. Sterile medium (no
starch), 4. 64 μg ampicillin, 5. 8 μg ampicillin, 6. 2 μg ampicillin, 7. 1 μg ampicillin, 8. 0
μg ampicillin.
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Subsequently, we examined if bacterial growth and the corresponding
carbohydrate uptake are affected by the presence of a particular antibiotic. After
incubating E. coli for 2 hours in the presence of ampicillin, we took 10-μL bacterial
culture aliquots in order to examine them using the dextran-coated polysaccharide
nanosensors. Thirty minutes after addition of Con A distinct changes in the T2 were
observed, indicating the presence of two cohorts (Figure 51A upper panel). Specifically,
the starch utilization and growth of E. coli were suppressed at ampicillin concentrations
above 8 μg, as demonstrated by the low changes in the ΔΤ2 compared to the sterile
medium. Furthermore, the nanoparticle-derived MIC of 8 μg was confirmed through the
turbidity method, which is the current gold standard for antimicrobial susceptibility
determination (Figure 51A lower panel). Although both assays provided identical results,
the dextran-coated polysaccharide nanosensor assay yielded faster results with an overall
time of 2.5 hours (2 hours for bacterial-antibiotic incubation and 30 minutes for
nanoparticle readout), as opposed to 24 hours. In addition, the nanosensor-based assay
requires smaller bacterial culture volumes (10 μL) as opposed to the turbidity MIC
method (2 mL). The latter is of particular logistics importance during epidemics and drug
discovery efforts, as it facilitates the simultaneous and cost-effective screening of
multiple samples, eliminating the need of tedious visual examination of numerous
cultures.
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Figure 51: Antimicrobial susceptibility screening in MH broth with dextran-coated
polysaccharide MRnS.
A) Determination of E. coli’s minimum inhibitory concentration in MH broth, using the
changes in spin-spin relaxation times (ΔT2, upper panel) (Means ± SE; p <0.05) and the
turbidity method (lower panel). B) Identification of S. marcescens’ resistance to
ampicillin via ΔΤ2 (upper panel, Means ± SE) and the turbidity assay (lower panel). The
corresponding amount of ampicillin is indicated in the graphs and pictures of the bacterial
cultures.

We further validated the antimicrobial susceptibility potential of dextran-coated
polysaccharide nanosensors using other bacteria. Shigella sonnie, a close relative of the
highly pathogenic Shiga-toxin producer Shigella dysenteriae, had an ampicillin MIC of 8
μg (Figure 52). Similar to E. coli, these results were also obtained within 2.5 hours. Then,
we investigated if our assay can determine bacterial drug resistance via the changes in
spin-spin relaxation time. As a model system, we used the hospital-acquired pathogen
Serratia marcescens129 . This pathogen is resistant to many antibiotics, including
ampicillin, due to the presence of resistance plasmids, and is used as a model organism
for bacterial drug resistance62,

130

. Thirty minutes after addition of Con A into the

nanoparticle solution, all samples exhibited similar ΔΤ2 values with no statistically
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significant differences, indicating that this pathogen is not susceptible to ampicillin
(Figure 51B upper panel). Confirmation of our results was achieved via the turbidity
method, where after 24 hours all cultures had a reddish turbid appearance, due to the
characteristic production of the pigment prodigiosin by S. marcescens131 (Figure 51B
lower panel).

Figure 52: Determination of the minimum inhibitory concentration of Shigella
sonnie.
A) Using the changes in spin-spin relaxation times (ΔT2) after a 30-min incubation at 25
o
C (Means ± SE; p <0.05), and B) with the turbidity method. The dotted line indicates the
threshold of the drug’s successful inhibition.

Due to the fact that many bacteria can either cause septicemia or require growth in
optically turbid media, it is important to assess bacterial susceptibility in these complex
matrices. However, most current methods cannot be utilized for the detection of
molecular targets and assessment of antimicrobial susceptibility in blood. This is due to
the strong absorbance and scattering from the matrix’s constituents, including platelets
and red blood cells (Figures 53 and 54).
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Figure 53: UV-vis profile of a bacterial culture growing in 5%-blood-supplemented
MH broth.
E. coli (106 CFU) were incubated for 2 hours at 37 o C in the presence of 4 μg ampicillin,
in 5%-blood-supplemented starch-containing MH broth. Then, a 50-μL bacterial culture
aliquot was diluted in 950 μL 1X PBS (Ca2+/Mg2+-free), resulting in similar to the
relaxation setup bacterial aliquot dilution. The strong absorbance of blood in the visible
spectrum suggests that optical-based methods spanning from 400 to 800 nm may not be
effective for MIC determination in this matrix.

Figure 54: DLS of 5%-blood-supple mented MH broth.
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Therefore, considering these drawbacks and the facts that bacterial isolation is a
major limitation step in diagnosis and that certain pathogenic microorganisms require
growth in specialized media, we examined if the dextran-coated polysaccharide MRnS
can assess antimicrobial susceptibility in blood. To address this, we used E. coli and S.
marcescens cultures in blood-supplemented MH broth, grown in the presence of
ampicillin for 2 hours at 37 o C. Aliquots of these cultures (10 μL) were obtained and
added into the dextran-coated polysaccharide nanosensors working solution, followed by
10-μL Con A treatment (1 μg/μL). After 45 minutes post-Con A addition at room
temperature, we determined that E. coli’s ampicillin MIC was 8 μg (Figure 55A), without
observing any nanoparticle precipitation (Figure 55C). Additionally, the S. marcescens’
drug resistance was identified after an hour- long incubation at 25 o C (Figure 55B).
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Figure 55: Determination of antimicrobial susceptibility in blood using dextrancoated polysaccharide MRnS.
A) Assessment of E. coli’s ampicillin MIC, and B) identification of S. marcescens’
ampicillin resistance in blood (Means ± SE; p <0.05). C) Blood cultures in nanoparticle
solution demonstrating the absence of nanoparticle precipitation and the optical nature of
the solution (numbers indicate the corresponding concentration of ampicillin in μ g).

Often times a slight modification in the nanosensors’ design and/or the protocol
followed can result in significant improvements in either the sensitivity or speed of the
assay132,
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. Therefore, we hypothesized whether conjugating Con A to the surface of

magnetic nanoparticles would achieve faster detection kinetics. For these experiments,
we conjugated Con A directly to aminated silica-coated iron oxide nanoparticles. We
chose silica-coated instead of dextran-coated iron oxide nanoparticles to avoid possible
cross reaction with the dextran on the nanoparticle’s surface. In this non-competition
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assay (Figure 56), the Con A-conjugated silica coated nanosensors would facilitate the
direct sensing of the levels of carbohydrates in solution, as opposed to the competition
assay that requires two reagents; the dextran-coated nanoparticles and the Con A for
successful sensing. The aminated silica-coated nanoparticles were synthesized using a
modified

water-based

synthetic protocol124 .

The resulting

nanoparticles

were

monodispersed, having a diameter of 145 nm (Figure 57A) and an R2 relaxivity of 225
mM-1 s-1 .

Figure 56: Schematic representation of the assessment of antimicrobial
susceptibility using Concanavalin A-conjugated polysaccharide MRnS.
The use of silica-coated nanoparticles and the direct conjugation of Con A to the capping
matrix result in a non-competition-based assay format, which may potentially provide
faster readout times.

129

Figure 57: Characterization of silica-coated IONP prior to Con A conjugation.
A) DLS of silica-coated IONP. B) Absence of Con A- induced clustering in silica-coated
IO nanoparticles, indicating the lack of carbohydrate-containing moieties on the
nanoparticles’ surface.

In our first set of experiments with the aminated silica-coated nanoparticles, we
determined whether these nanoparticles clustered non-specifically in the presence of Con
A in solution. As expected, we observed that Con A did not induce any changes in the
relaxation times of the nanoparticles (Figure 57B). This demonstrates that the silica
coating on these nanoparticles lacks any carbohydrate epitopes, rendering them suitable
for the non-competition-based sensing of carbohydrates. Therefore, we conjugated Con A
to the aminated silica-coated nanoparticles, via carbodiimide chemistry, resulting in Con
A-carrying nanoparticles with a hydrodynamic diameter of ~160 nm (Figure 58) (R2 =
225 mM-1 s-1, [Con A] = 0.03 μg/μL).
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Figure 58: DLS of Concanavalin A-conjugated polysaccharide MRnS.

Next, we compared the kinetic profiles of the dextran-coated nanosensors and
Con A-conjugated nanosensors using bacterial E. coli blood cultures (106 CFU grown in
the presence of 2 μg ampicillin). Interestingly, we found that the non-competition assay
with the Con A-conjugated MRnS (Figure 59, curve B) provided faster results than the
competition assay that utilizes the dextran-coated MRnS (Figure 59, curve A).
Specifically, the competition assay format reached its end-point after a 45- minute
incubation, whereas the non-competition assay reaches its end-point within 5 minutes
upon addition of the bacterial sample. These findings support our hypothesis of achieving
faster kinetics due to the direct conjugation of Con A to the nanoparticles.
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Figure 59: Kinetic profiles of the competition and non-competition assay formats.
Point A represents the end-point of the competition assay utilizing the dextran-coated
polysaccharide MRnS, whereas Point B corresponds to the end-point of the noncompetition assay based on the Con A-conjugated polysaccharide MRnS.

We finally examined if MIC determination can be achieved using these Con Aconjugated MRnS, in blood cultures of E. coli and S. marcescens. Immediately upon
addition of the bacterial sample into the nanoparticle solution, distinct changes in the T2
were observed. Specifically, within 5 minutes the Con A- nanosensors were able to
determine that E. coli had an ampicillin MIC of 8 μg (Figure 60A), in line with the data
from the dextran-coated nanosensors in the competition assay or the turbidity test.
Likewise, within 5 minutes the Con A-conjugated nanosensors assessed that S.
marcescens was resistant to ampicillin, further corroborating the findings that the noncompetition assay format provides faster results than the competition-based assay of the
dextran-coated MRnS (Figure 60B).
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Figure 60: Antimicrobial susceptibility in blood using Con A-conjugated
polysaccharide MRnS.
A) Determination of E. coli’s ampicillin MIC in blood, and B) determination of Serratia
marcescens’ drug resistance in blood with the Con A-conjugated polysaccharide MRnS,
five minutes after addition of the bacterial aliquot into the nanoparticle solution (Means ±
SE; p <0.05).
Conclusion
 Spectrophotometric assessment of antimicrobial susceptibility can be quickly and
reliably achieved using dextran-coated gold nanoparticles.
 High-throughput screening and determination of MIC can be easily achieved
using the discrete clustering of dextran-coated gold nanosensors.
 Polysaccharide-sensing MRnS can assess bacterial metabolism through magnetic
relaxation.
 MRnS can determine MIC and bacterial drug resistance in opaque media,
including blood.
 Conjugation of Con A to MRnS improves detection kinetics, leading to faster
determination of antimicrobial susceptibility than MRnS in competition format.
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Discussion
Fast identification and administration of the most effective antimicrobial agents is
critical for control of bacterial infections. In particular, the emergence of multidrug
resistant bacterial strains makes the fast and accurate identification of these pathogens
and their susceptibility to antibiotics critical for treatment decision making. As most
antimicrobial susceptibility methods require extensive incubations hampering the
expedite assessment of drug resistance, we utilized nanosensors in an effort to improve
readout times without compromising reliability and sensitivity. Our results indicate that
gold nanosensors within less than 3 hours can spectrophotometrically identify if a
pathogen is resistant to antibiotics or not. Comparing these results with the workhorse
antimicrobial susceptibility assays of the turbidity method or disk diffusion, the
nanoparticle-based methodologies are equally sensitive and reliable, yet high-throughput
capable and do not need overnight or daylong incubations.
However, considering that antimicrobial susceptibility has to be frequently
performed in clinical and opaque samples, we utilized MRnS for MIC determination. We
demonstrated that MRnS, either dextran-coated supplemented with Con A or Con Aconjugated, can be used for the quantification of polysaccharides, the assessment of
metabolic activity and determination of antimicrobial susceptibility in complex matrices,
such as blood, through magnetic relaxation. This approach is an alternative to opticalbased assays, which cannot be utilized in opaque media. Additionally, both MRnS assay
formats require minute sample volumes, are equally reliable to established methods, and
do not require any sample preparation, contrary to other techniques. Intriguingly, a
simple modification to the MRnS design by directly conjugating Con A to the
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nanosensors resulted in more sensitive polysaccharide-sensing MRnS. The Con Aconjugated polysaccharide nanosensor assay yielded faster results, without compromising
sensitivity and reliability, due to faster binding kinetics. Also, as there is no need for the
addition of a second reagent (Con A), this format might be particularly useful for pointof-care diagnostics and field applications.
Concluding, we anticipate that the MRnS, similar to the gold nanosensors, can be
easily adapted for the high-throughput screening of multiple clinical and environmental
samples, preventing epidemics and promoting drug discovery. In view of the recent
advancements in NMR technology58, 86, 134 , the high- throughput and/or field analysis of
multiple samples in complex media should be feasible, even outside of the typical
laboratory setting. Overall, we believe that these assays can expedite clinical decisionmaking and may facilitate the faster discovery of potential antimicrobial agents through
the screening of combinatorial libraries and environmental sample fractionations.
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CHAPTER VI: GENERAL CONCULSION –“IT’S ONLY THE
BEGINNING …”
Molecular recognition events are characterized by unique fidelity, strong affinity
and remarkable specificity, through the fine-tuning of multiple interactions and
optimization of structural components via evolutionary and selection processes. From
antibodies and antigens to receptors and ligands, nature is able to perform a plethora of
life supporting functions, including extracellular milieu sensing, matrix attachment,
pathogen recognition, nutrient uptake, proofreading, and signal transduction. The second
half of the 20th century experienced the birth of molecular diagnostics and the expansion
of biological sciences. Consequently, humanity for the first time was able to achieve
understanding of basic cellular and sub-cellular events that led to an expansion of the
published literature and propelled the development of novel therapeutics and treatment
regimes. However, at the end of that century, researchers geared their efforts towards
rational design of nanoparticle-based diagnostics, in order to achieve more sensitive
diagnostic methods with improved detection thresholds and kinetics. A particular
challenge of this approach is the inherent complexity of these nanoparticle-based
systems,

requiring

materials

optimization,

rigorous

testing,

instrumentation

advancements, as well as efficient coupling and modifying chemistries.
In parallel though, determination of how the fine-tuning of existing systems can
evolve molecular diagnostics has provided us with more encouraging results, particularly
in the emerging fields of nanotechnology-based diagnostic modalities. For instance in this
work, we have demonstrated how the nanoparticles’ polymeric coating can modulate
intrinsic properties of iron oxide nanoparticles, such as their peroxidase-like activity.

136

Furthermore, we discovered that the valency of magnetic relaxation nanosensors plays a
pivotal role in the relaxation- mediated detection pattern, as well as detection range and
kinetics. Reminiscent of biological entities such as viruses, MRnS with high valency
were able to quickly detect a single cancer cell in blood samples, due to the abundance of
a small ligand found on the nanoparticles. Apart from cancer cells, we were able to detect
bacteria, nucleic acid markers, and toxins with high specificity, using a single instrument
(relaxometer). Notably, by utilizing a protein that has high affinity to carbohydrates and
MRnS, we were able to monitor metabolic activity and quickly assess bacterial drug
resistance. This demonstrates that rational selection of existing molecular components
and the fine-tuning of nanostructures can synergistically lead to the creation of
ultrasensitive probes that use existing instrumentation, propelling drug discovery and
point-of-care diagnostics.
Overall, nanotechnology is poised to revolutionize the way how pathogen and
infectious diseases diagnostics are performed in the 21 st century. By enabling the fast,
cost effective and sensitive detection of infectious agents, engineered nanoprobes and
nanodevices have the potential to facilitate the robust and high- throughput screening of
pathogens in biological and environmental samples. This can be achieved via the unique
interactions these nanoprobes and nanodevices have upon recognition of the molecular
target or pathogen.

Inorganic nanoparticles, semiconductor quantum dots, carbon

nanotubes, polymeric nanoparticles, as well as cantilevers and nanochips, all have the
potential to be useful in the design of sensitive pathogen diagnostics. Particularly,
nanoparticles are versatile, because in principle could substitute the use of fluorescence
molecules as tags in most diagnostics applications. Future trends in nanotechnology will
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be the design of nanostructures to build miniaturized devices, requiring smaller sample
volumes. In addition, as the field of nanotechnology progresses into the design of smart
2-D and 3-D nanoassemblies, new devices that facilitates fast and sensitive pathogen
detection in minimal sample volumes are expected. As drug resistance strains continue to
emerge, in the forthcoming years we would expect the design of nanosystems that not
only are able to sense the presence of a pathogen, but also assess if this pathogen is
resistant to a particular drug. Finally, we believe that we are at the dawn of
nanomedicine, and more exciting discoveries should be expected as part of the eternal
processes of improvement, intellectuality and imagination.
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